{"gene":"KLF5","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":1993,"finding":"KLF5 (BTEB2) encodes a GC box-binding protein with three C-terminal zinc finger motifs that binds DNA with specificity similar to Sp1 and activates transcription through a proline/serine/threonine/alanine-rich N-terminal region; recombinant BTEB2 expressed in E. coli showed sequence-specific DNA-binding activity, and cotransfection experiments demonstrated transcriptional activation of GC box-containing reporters.","method":"cDNA cloning, recombinant protein DNA-binding assay, cotransfection reporter assay, GAL4 fusion transactivation assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro DNA-binding reconstitution plus multiple orthogonal functional assays (EMSA, reporter, GAL4 fusion) in a single foundational study","pmids":["8479902"],"is_preprint":false},{"year":1997,"finding":"The transcriptional activation domain of KLF5 (BTEB2) resides in a ~10-amino-acid hydrophobic, proline/alanine-rich region within the proline-rich N-terminal domain; purified BTEB2 enhanced transcription in an in vitro transcription assay in a GC-box-dependent manner, and this activity was abolished by deletion of the hydrophobic region. Basic transcription factors TFIIB, TFIIEβ, TFIIFβ, and TBP were found to interact with BTEB2 by in vitro binding experiments.","method":"In vitro transcription assay with purified protein, deletion/point-mutation analysis, in vitro binding (pulldown) with basal transcription factors","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of transcription activity plus mutagenesis plus direct binding assays in one study","pmids":["9089417"],"is_preprint":false},{"year":1999,"finding":"KLF5 (BTEB2) binds the SE1 cis-regulatory element in the SMemb/NMHC-B gene promoter and activates its transcription in smooth muscle cells; a GST-BTEB2 fusion protein bound SE1 in a sequence-specific manner, BTEB2 was identified as a major component of the nuclear factor:SE1 complex by gel-shift and antibody supershift, and disruption of SE1 abolished basal and BTEB2-induced promoter activity.","method":"Gel mobility shift assay, antibody supershift, GST pulldown/DNA-binding assay, luciferase reporter with site-directed mutagenesis, immunohistochemistry","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal in vitro assays (EMSA, supershift, GST-DNA binding, mutagenesis of cis-element) in one study","pmids":["10417400"],"is_preprint":false},{"year":1999,"finding":"KLF5 (BTEB2) expression in vascular smooth muscle cells is transcriptionally activated by PMA and bFGF via an Egr-1 binding site (5'-CGCCCGCGC-3') located at -25 in the BTEB2 promoter, acting through the MAP kinase pathway; site-specific mutation of the Egr-1 site abolished inducible promoter activity.","method":"Luciferase reporter assay, site-directed mutagenesis, EMSA (DNA-protein complex characterization), pharmacological inhibition of MAPK pathway","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — promoter dissection with mutagenesis plus EMSA plus pathway inhibition in one study","pmids":["10532946"],"is_preprint":false},{"year":1999,"finding":"Full-length human KLF5 (IKLF) encodes a 457-amino-acid nuclear protein that binds the CAAT/GT box (EGFRE) of the mouse lactoferrin gene promoter and represses reporter gene activity in RL95-2 endometrial carcinoma cells; nuclear localization was confirmed by GFP-tagged IKLF transfection and Western fractionation.","method":"DNase I footprinting, EMSA, GFP-tagging/fluorescence microscopy, Western blot of nuclear fractions, luciferase reporter assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct DNA-binding assays (footprinting, EMSA) plus localization and functional reporter in one study","pmids":["10572182"],"is_preprint":false},{"year":2001,"finding":"KLF5 (mBTEB2) is a transcriptional target of Wnt-1 signaling; its induction in C57MG cells occurs through a β-catenin/Lef-TCF-independent, PKC-sensitive noncanonical Wnt pathway, as shown by cDNA subtractive hybridization and pharmacological PKC manipulation.","method":"cDNA subtractive hybridization, transgenic mouse mammary gland analysis, PKC pharmacological inhibition, reporter assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic/pharmacological pathway dissection in two model systems (cell line and transgenic mouse tissue), single lab","pmids":["11134343"],"is_preprint":false},{"year":2002,"finding":"KLF5 is induced by angiotensin II and in turn activates PDGF-A and TGF-β expression; KLF5 physically interacts with the retinoic acid receptor (RAR), and synthetic RAR ligands modulate KLF5 transcriptional activity; heterozygous Klf5-knockout mice showed diminished cardiovascular remodeling responses, and homozygous knockout caused early embryonic lethality.","method":"Heterozygous knockout mouse model, chromatin immunoprecipitation (ChIP) for PDGF-A promoter binding, co-immunoprecipitation (KLF5–RAR interaction), luciferase reporter assay, in vivo pharmacology with RAR ligands","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in vivo plus ChIP plus protein–protein interaction plus pharmacological modulation, independently replicated aspects across multiple follow-up papers","pmids":["12101409"],"is_preprint":false},{"year":2003,"finding":"KLF5 transactivation is enhanced by CBP; the interaction maps to the N-terminal region of CBP (aa 1–232) and the N-terminal region of KLF5 (aa 1–238). Phosphorylation at a PKC site within the CBP-interaction domain of KLF5 is required for full transactivation, as shown by kinase inhibitors and site-directed mutagenesis, and phosphorylation of KLF5 enhances its interaction with CBP in GST pulldown assays. The HAT activity of CBP does not acetylate KLF5 in vitro.","method":"GAL4 fusion transactivation assay, co-immunoprecipitation, GST pulldown, site-directed mutagenesis (PKC phosphorylation site), pharmacological kinase inhibition (H7, calphostin C)","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (reporter, Co-IP, GST pulldown, mutagenesis, kinase inhibition) in one study","pmids":["12682370"],"is_preprint":false},{"year":2003,"finding":"KLF5 binds the TCR Dbeta1 promoter GC-rich motifs and transactivates Dbeta1 germline transcription in pro-T cells; antibody supershift and chromatin immunoprecipitation confirmed endogenous KLF5 occupancy at the Dbeta1 promoter; a dominant-negative KLF5 construct inhibited reporter expression.","method":"Yeast one-hybrid screening, antibody supershift EMSA, chromatin immunoprecipitation (ChIP), luciferase reporter assay with dominant-negative construct","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP of endogenous locus plus dominant-negative functional validation plus EMSA supershift in one study","pmids":["12576331"],"is_preprint":false},{"year":2004,"finding":"In non-transformed intestinal epithelial cells, KLF5 enhances cyclin D1 transcription and promotes cell growth; however, Ras-mediated transformation switches KLF5 function so that it reduces colony formation and no longer enhances cyclin D1 transcription, demonstrating context-dependent altered function during tumor progression. KLF5 protein is destabilized in transformed cells.","method":"Stable retroviral expression, colony formation assay, cyclin D1 luciferase reporter, Ras transformation model, protein stability analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function in isogenic cell pairs plus reporter assays, single lab","pmids":["14726538"],"is_preprint":false},{"year":2011,"finding":"TAZ stabilizes KLF5 protein by antagonizing WWP1-mediated ubiquitination; TAZ interacts with the PY motif of KLF5 through its WW domain, competing with the E3 ubiquitin ligase WWP1 for the same binding site, thereby inhibiting WWP1-mediated KLF5 ubiquitination and proteasomal degradation. This was shown to require the WW domain of TAZ and promotes breast cell proliferation.","method":"Co-immunoprecipitation, ubiquitination assay, WW-domain mutant TAZ overexpression, siRNA knockdown, xenograft tumor model","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ubiquitination assay with domain-mutant controls, and in vivo rescue, single lab but multiple orthogonal methods","pmids":["22045023"],"is_preprint":false},{"year":2012,"finding":"YAP interacts with KLF5 through its WW domains binding the PY motif of KLF5, preventing WWP1 E3 ligase from ubiquitinating KLF5, thereby stabilizing KLF5 protein and upregulating KLF5 target genes (FGFBP1/FGF-BP and ITGB2). LATS1 (upstream kinase of YAP) suppresses the KLF5-FGF-BP axis through YAP.","method":"Co-immunoprecipitation, WW-domain mutant YAP overexpression, siRNA knockdown, xenograft tumor model, target gene expression analysis","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain-mutant controls, epistasis via LATS1 knockdown, and in vivo xenograft, single lab multiple methods","pmids":["22632819"],"is_preprint":false},{"year":2014,"finding":"FBW7 (FBXW7/CDC4) is an E3 ubiquitin ligase that targets KLF5 for ubiquitination and proteasomal degradation; KLF5 contains functional Cdc4 phospho-degrons (CPDs) required for FBW7 interaction; GSK3β phosphorylates these CPDs, and mutation of CPDs blocks FBW7-mediated ubiquitination and degradation of KLF5.","method":"Ubiquitination assay, co-immunoprecipitation, site-directed mutagenesis of phospho-degrons, GSK3β kinase involvement, cancer cell line and mouse model analysis","journal":"World journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanism reviewed and integrated from primary studies; CPD mutagenesis and Co-IP data cited from original papers by same group","pmids":["24921010"],"is_preprint":false},{"year":2015,"finding":"BAP1 is a deubiquitinase (DUB) for KLF5; BAP1 directly interacts with KLF5 and stabilizes it via deubiquitination. KLF5 is present in the BAP1/HCF-1 complex. BAP1 knockdown inhibits tumorigenicity and lung metastasis, which is partially rescued by ectopic KLF5 expression. Identified by genome-wide siRNA DUB library screen.","method":"Genome-wide siRNA library screen, co-immunoprecipitation, deubiquitination assay, BAP1 knockdown with KLF5 rescue, xenograft/metastasis model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased genome-wide screen plus Co-IP plus biochemical DUB assay plus in vivo rescue experiment","pmids":["26419610"],"is_preprint":false},{"year":2015,"finding":"Cardiac myocyte KLF5 directly activates PPARα (Ppara) gene expression by binding its promoter; cardiac myocyte-specific Klf5 knockout mice showed reduced Ppara expression, reduced fatty acid oxidation, decreased ATP, increased triglyceride accumulation, and cardiac dysfunction. In septic hearts, c-Jun competes with KLF5 at an overlapping site on the Ppara promoter to repress transcription.","method":"Cardiac myocyte-specific knockout mouse, ChIP (KLF5 promoter binding), luciferase reporter assay, metabolic assays (FAO, ATP), co-IP or competitor binding analysis","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — tissue-specific KO with defined metabolic phenotype plus direct ChIP evidence of promoter binding, replicated concept across diabetes and sepsis models","pmids":["26574507"],"is_preprint":false},{"year":2017,"finding":"In macrophages, KLF5 promotes podosome formation and cell migration by directly activating transcription of Myo9b (myosin IXB) through binding its promoter; KLF5 acts upstream of RhoA signaling (KLF5 knockdown increased RhoA-GTP levels); myeloid-specific Klf5 knockout mice showed impaired macrophage infiltration and reduced AAA formation.","method":"Myeloid-specific Klf5 knockout mice, luciferase reporter assay (Myo9b promoter), co-immunostaining, time-lapse migration imaging, RhoA-GTP pulldown assay","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO in vivo plus reporter assay with direct binding plus RhoA activity measurement, multiple orthogonal methods","pmids":["28115390"],"is_preprint":false},{"year":2018,"finding":"HDAC1/2 deacetylate KLF5 at K369 and promote its proteasomal degradation; the deacetylase activity of HDAC1/2 is required for KLF5 degradation. An acetylation-mimicking K369Q mutation of KLF5 prevents its proteasomal degradation even though it does not affect HDAC1/2 binding. Maintaining KLF5 in a deacetylated state promotes cell proliferation.","method":"siRNA knockdown of HDAC1/2, site-directed mutagenesis (K369Q, K369R), cycloheximide chase/protein stability assay, co-immunoprecipitation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus stability assay plus Co-IP, single lab","pmids":["29679567"],"is_preprint":false},{"year":2019,"finding":"USP3 is a deubiquitinase for KLF5; USP3 interacts with KLF5 and stabilizes it via deubiquitination; USP3 knockdown inhibits breast cancer cell proliferation and tumorigenesis, which is partially rescued by ectopic KLF5 expression. Identified by genome-wide siRNA DUB library screening.","method":"Genome-wide siRNA DUB library screen, co-immunoprecipitation, deubiquitination assay, USP3 knockdown with KLF5 rescue, in vivo tumorigenesis model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — unbiased screen plus biochemical DUB assay plus in vivo rescue, single lab multiple methods","pmids":["31624151"],"is_preprint":false},{"year":2020,"finding":"KLF5 directly binds the promoter of NOX4 (NADPH oxidase 4) to activate its transcription; FOXO1 binds directly to the KLF5 promoter to increase KLF5 expression in diabetic cardiomyocytes; KLF5-induced NOX4 upregulation causes oxidative stress and ceramide accumulation leading to diabetic cardiomyopathy; cardiomyocyte-specific FOXO1 deletion reduced KLF5, and AAV-mediated KLF5 re-expression abolished this protection.","method":"ChIP (FOXO1 on KLF5 promoter; KLF5 on NOX4 promoter), cardiomyocyte-specific FOXO1 knockout mice, AAV-mediated KLF5 overexpression/rescue, pharmacological KLF5 inhibition, ROS/ceramide measurement","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP for direct promoter binding plus genetic KO plus AAV rescue in multiple mouse models with orthogonal biochemical readouts","pmids":["33539225"],"is_preprint":false},{"year":2020,"finding":"Klf5 down-regulation in vascular smooth muscle cells leads to mitochondrial fission and vascular senescence; mechanistically, Klf5 directly activates eIF5a transcription by binding its promoter, and eIF5a in turn preserves mitochondrial integrity by interacting with mitofusin 1 (Mfn1). VSMC-specific Klf5 knockout mice showed exacerbated vascular senescence and AAA progression.","method":"VSMC-specific Klf5 knockout mice, ChIP (Klf5 binding to eIF5a promoter), co-immunoprecipitation (eIF5a–Mfn1 interaction), ROS measurement, mitochondrial imaging","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO plus ChIP plus Co-IP in same study, multiple orthogonal methods","pmids":["32817651"],"is_preprint":false},{"year":2020,"finding":"Acetylated KLF5 (at K369) is the predominant form in basal prostate cells and is essential for proper luminal differentiation from basal progenitors; deacetylation of Klf5 (K369R knock-in) causes excess basal-to-luminal differentiation and activates Notch signaling; acetylated Klf5 maintains basal progenitors and coordinates postnatal prostate development.","method":"Acetylation-specific KLF5 K369R knock-in mouse, organoid assay, Notch signaling readout, cell lineage tracing, Western blot with acetylation-specific antibody","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — constitutive knock-in mouse model for a specific PTM plus organoid assays plus pathway readout, multiple orthogonal approaches","pmids":["32081850"],"is_preprint":false},{"year":2020,"finding":"KLF5 is a transcriptional regulator of skeletal muscle atrophy; KLF5 is up-regulated early in atrophying myotubes and skeletal muscle-selective Klf5 deletion attenuates mechanical unloading-induced atrophy in mice. KLF5 regulates atrophy-related metabolic and E3-ubiquitin ligase programs in coordination with Foxo1; the RAR agonist Am80 inhibits KLF5 and suppresses muscle atrophy.","method":"Skeletal muscle-specific Klf5 knockout mice, transcriptome profiling, chromatin accessibility analysis (ATAC-seq), pharmacological inhibition with Am80 (RAR agonist/KLF5 inhibitor), dexamethasone and simulated microgravity atrophy models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO mouse plus genome-wide chromatin and transcriptome analyses plus pharmacological rescue, multiple models","pmids":["34426497"],"is_preprint":false},{"year":2021,"finding":"PRMT5 interacts with KLF5 and catalyzes di-methylation of KLF5 at Arginine 57 (R57) in a methyltransferase-activity-dependent manner; PRMT5-induced KLF5 R57me2 antagonizes GSK3β-mediated KLF5 phosphorylation and subsequently Fbw7-mediated ubiquitination and degradation, thereby stabilizing KLF5 and promoting breast cancer stem cell maintenance and proliferation.","method":"Co-immunoprecipitation, in vitro methylation assay, site-directed mutagenesis (R57), phosphorylation and ubiquitination assays, PRMT5 inhibitor (PJ-68), xenograft model","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro methylation assay plus mutagenesis of target site plus downstream PTM crosstalk analysis plus pharmacological and genetic validation in vivo","pmids":["33972717"],"is_preprint":false},{"year":2021,"finding":"KLF5 and AR physically interact on chromatin in prostate cancer cells and drive opposing transcriptional programs; KLF5 promotes cellular migration, anchorage-independent growth, and basal epithelial phenotypes while antagonizing AR activity. ERBB2 is identified as a point of transcriptional convergence activated by KLF5 and repressed by AR.","method":"Co-immunoprecipitation on chromatin, ChIP-seq, RNA-seq, gain- and loss-of-function (KLF5 overexpression/knockdown), ERBB2 inhibitor treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — chromatin Co-IP plus ChIP-seq plus transcriptomic plus functional assays, single lab multiple orthogonal methods","pmids":["34737261"],"is_preprint":false},{"year":2021,"finding":"YB-1 enhances KLF5 expression by: (1) transcriptional activation that can be inhibited by DACH1, and (2) stabilizing KLF5 mRNA in an RNA 5-methylcytosine modification-dependent manner. RSK2-mediated YB-1 phosphorylation at Ser102 promotes YB-1/KLF5 transcriptional complex formation, which co-regulates KRT16 and Ly6D expression to promote basal-like breast cancer cell proliferation.","method":"Co-immunoprecipitation, mRNA stability assay, site-directed mutagenesis (YB-1 Ser102), ChIP, luciferase reporter, RSK inhibitor (LJH685) in vivo","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus mRNA stability plus mutagenesis, single lab","pmids":["35022570"],"is_preprint":false},{"year":2021,"finding":"KLF5 directly binds the promoter of COX2 and promotes its transcription; KLF5 deficiency decreases PGE2 release from tumor cells by reducing COX2 expression, thereby increasing CD8+ T-cell infiltration and function in the tumor microenvironment; inhibition of the KLF5/COX2 axis synergizes with anti-PD1 therapy.","method":"ChIP (KLF5 on COX2 promoter), luciferase reporter assay, RNA-seq, KLF5 knockout/overexpression in tumor cells, flow cytometry (T-cell infiltration), mouse tumor models","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus in vivo functional assays, single lab","pmids":["36923542"],"is_preprint":false},{"year":2021,"finding":"Klf5 establishes bi-potential cell fate in early mouse embryos by dual regulation: Klf5 directly induces both ICM specification genes and TE specification genes; Klf5 acts redundantly with Klf4 during ICM specification but Klf5 alone is required for TE specification. Klf5 is regulated by the 2C-specific factor Dux, and the Dux/Klf5 axis is evolutionarily conserved.","method":"ChIP-seq (direct target identification), Klf5 knockout embryos, chimeric embryo assay with Klf5-overexpressing ESCs, genetic epistasis (Klf5/Klf4 double mutant)","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq plus genetic KO plus chimeric embryo rescue plus epistasis analysis, multiple orthogonal approaches","pmids":["34758315"],"is_preprint":false},{"year":2022,"finding":"WWP2 monoubiquitinates KLF5 via its catalytic Cys838; monoubiquitination (not polyubiquitination/degradation) of KLF5 by WWP2 transactivates KLF5, promoting expression of downstream odontoblast differentiation genes Dmp1 and Dspp. WWP2 interaction requires the PY2 motif (PPPSY) of KLF5. Lysine residues K31, K52, K83, and K265 of KLF5 are essential for WWP2-mediated transactivation.","method":"Co-immunoprecipitation, ubiquitination assay (K48-linkage analysis), site-directed mutagenesis (WWP2 C838A, KLF5 PY2 motif, KLF5 lysine residues), siRNA knockdown, ALP/Alizarin Red differentiation assays","journal":"Journal of dental research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — biochemical ubiquitination assay with active-site mutagenesis plus substrate residue mapping plus functional differentiation readout, single lab multiple methods","pmids":["33164644"],"is_preprint":false},{"year":2022,"finding":"HDACi (SAHA, TSA) increase KLF5 acetylation at K369 and promote its proteasomal degradation via ubiquitination; K369 acetylation decreases binding of KLF5 to its deubiquitinase BAP1, thus reducing KLF5 stability. This reveals a crosstalk between KLF5 acetylation (K369) and its ubiquitination/stability.","method":"Western blot with acetylation-specific antibody, ubiquitination assay, co-immunoprecipitation (KLF5–BAP1 interaction with K369 mutants), SAHA/TSA treatment, site-directed mutagenesis (K369)","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with acetylation mutants plus ubiquitination assay, single lab","pmids":["35342356"],"is_preprint":false},{"year":2022,"finding":"Klf5 is an essential determinant of AT1 alveolar epithelial cell lineage fidelity during lung development; Klf5 represses AT2 cell proliferation and enhances AT2-to-AT1 cell differentiation in a spatially restricted manner during lung regeneration; Klf5 reduces AT2 cell sensitivity to inflammatory signaling to drive AT2-AT1 differentiation, as shown in infectious and non-infectious ARDS models.","method":"Cell-type-specific Klf5 conditional knockout mice, organoid assay, transcriptomic and epigenetic profiling, lung injury models (ARDS)","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO in multiple disease models plus organoid assays plus transcriptomic/epigenetic profiling","pmids":["35803279"],"is_preprint":false},{"year":2022,"finding":"α-Catulin interacts with the C-terminal region of KLF5 and inhibits WWP1-mediated degradation of KLF5, thereby stabilizing KLF5 and promoting cancer stem-like properties in non-small cell lung cancer; ILK inhibition disrupts the α-Catulin–KLF5 interaction and promotes KLF5 degradation.","method":"Yeast two-hybrid, co-immunoprecipitation, cycloheximide chase assay, ILK inhibitor treatment, sphere formation and xenograft assays","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus protein stability assay, single lab","pmids":["35154481"],"is_preprint":false},{"year":2023,"finding":"SRC kinase-mediated tyrosine phosphorylation of YAP1 induces YAP1 interaction with KLF5 to form a YAP1/TEAD-KLF5 transcriptional complex; this complex promotes TEAD-mediated transcription independently of canonical Hippo kinases, driving cancer stemness and metastasis in TNBC.","method":"Co-immunoprecipitation, SRC inhibition, phospho-YAP1 mutant analysis, transcriptomic and proteomic analysis, TNBC xenograft and metastasis models","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus phospho-mutant analysis plus in vivo functional assays, single lab","pmids":["36633714"],"is_preprint":false},{"year":2023,"finding":"KLF5 forms a transcriptional complex with EHF and ELF3 and binds to the promoter region of RAD51 to enhance its transcription, strengthening the homologous recombination repair (HRR) pathway; super-enhancers drive relative cancer-specific expression of KLF5 in ovarian cancer.","method":"ChIP (KLF5 on RAD51 promoter), co-immunoprecipitation (KLF5–EHF–ELF3 complex), super-enhancer analysis, luciferase reporter, functional HRR assay","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP plus reporter, single lab","pmids":["37702443"],"is_preprint":false},{"year":2023,"finding":"PRMT5 interacts with KLF5 and catalyzes dimethylation of KLF5 at Arginine 41 in lung cancer cells in a methyltransferase-activity-dependent manner; this methylation stabilizes KLF5 by promoting the Akt/GSK3β signaling axis, and PRMT5 depletion/inhibition reduces KLF5 expression and downstream targets.","method":"Co-immunoprecipitation, in vitro methylation assay, PRMT5 inhibitor treatment, Akt/GSK3β pathway analysis, siRNA knockdown, in vivo tumor model","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus methylation assay plus pathway analysis, single lab; note discrepancy in methylated Arg residue (R57 in breast cancer [33972717] vs R41 here — different contexts/residues reported)","pmids":["37461162"],"is_preprint":false},{"year":2024,"finding":"PTEN deficiency induces KLF5 acetylation; deacetylated KLF5 in prostate cancer cells promotes secretion of TNF-α, which stimulates cancer-associated fibroblasts (CAFs) to release FGF9; FGF9 activates FGFR1 signaling in cancer cells, enhancing tumor growth; CX3CR1 inhibition blocked FGFR1 activation and sensitized PTEN-deficient prostate cancer to AKT inhibitor capivasertib.","method":"Klf5 acetylation knock-in mouse, co-culture assays (cancer cell–CAF interaction), cytokine ELISA, FGFR1 signaling analysis, pharmacological inhibition (CX3CR1 inhibitor + AKT inhibitor)","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knock-in mouse plus co-culture mechanistic dissection plus pharmacological rescue, single lab","pmids":["38781024"],"is_preprint":false},{"year":2024,"finding":"Histone H3 lysine 14 lactylation (H3K14la), driven by elevated lactate in diabetic kidney disease, facilitates KLF5 expression at the chromatin level; KLF5 then binds the cdh1 (E-cadherin) promoter and inhibits its transcription, accelerating epithelial-mesenchymal transition. ChIP-seq revealed H3K14la at the KLF5 locus and RNA-seq linked this to EMT gene programs.","method":"ChIP-seq (H3K14la at KLF5 locus), RNA-seq, ChIP (KLF5 binding to cdh1 promoter), lactate reduction experiments, nephron-specific KLF5 knockdown mouse, KLF5 inhibitor (ML264)","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus ChIP plus nephron-specific KO, single lab","pmids":["38925041"],"is_preprint":false},{"year":2018,"finding":"KLF5 deacetylation (by HDAC1/2) is linked to its proteasomal degradation: silencing HDAC1/2 upregulates KLF5 protein without affecting mRNA, through reduced proteasomal degradation. An acetylation-mimicking K369Q mutation prevents KLF5 degradation, while a K369R mutation (blocks acetylation) does not affect HDAC1/2 binding or KLF5 degradation response.","method":"siRNA knockdown, cycloheximide chase, proteasome inhibitor MG132, site-directed mutagenesis (K369Q, K369R), co-immunoprecipitation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus protein stability assay plus Co-IP, single lab","pmids":["29679567"],"is_preprint":false},{"year":2018,"finding":"KLF5 promotes cell migration and lamellipodia formation in bladder cancer by transcriptionally activating FYN through direct binding to the FYN promoter; KLF5 overexpression increases FYN expression and FAK phosphorylation; FYN overexpression rescues migration reduced by KLF5 knockdown, placing KLF5 upstream of FYN in a KLF5/FYN/p-FAK migration axis.","method":"ChIP (KLF5 on FYN promoter), luciferase reporter assay, siRNA knockdown, FYN rescue experiment, lamellipodia imaging","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus epistasis rescue, single lab","pmids":["26786295"],"is_preprint":false},{"year":2020,"finding":"In cancer chromatin, KLF5 interacts with TP63 and YAP1 transcription factors and with the CBP/EP300 acetyltransferase complex; KLF5 guides the CBP/EP300 complex to increase H3K27 acetylation, which enhances BRD4 recruitment; 3D chromatin looping (HiChIP) aggregates multiple distal KLF5 binding events to synergistically activate individual target genes and drive RNA Pol II elongation.","method":"HiChIP (3D chromatin architecture), immunoprecipitation-mass spectrometry (KLF5 interactome), ChIP-seq (H3K27ac, BRD4), PROTAC-mediated BRD4 degradation, KLF5 dependency screen","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — IP-MS interactome plus HiChIP 3D architecture plus ChIP-seq plus functional PROTAC validation, multiple orthogonal methods","pmids":["33115806"],"is_preprint":false},{"year":2021,"finding":"KLF5 is indispensable for maintaining basal progenitors in the intestinal stem cell niche; inducible deletion of Klf5 in Lgr5+ stem cells suppressed their proliferation and survival, associated with nuclear β-catenin localization and abnormal apoptosis; oncogenic β-catenin-driven adenoma/carcinoma production in Lgr5+ cells was completely suppressed by Klf5 deletion in the same cells, placing KLF5 downstream of or required for Wnt/β-catenin oncogenesis.","method":"Inducible Lgr5-specific Klf5 knockout mice, β-catenin nuclear localization analysis, oncogenic β-catenin knock-in crossed with Klf5 deletion, histological analysis of adenoma/carcinoma formation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible cell-type-specific KO plus oncogenic epistasis rescue, in vivo genetic model","pmids":["24626089"],"is_preprint":false},{"year":2018,"finding":"Klf5 suppresses ERK signaling in mouse embryonic stem cells; Klf5-knockout ESCs showed over-activated ERK, reintroduction of Klf5 (but not Klf2 or Klf4) suppressed ERK. Klf5 regulates Spred1, a negative regulator of the FGF-ERK pathway, providing a molecular mechanism for ERK suppression.","method":"Klf5-KO ESC lines, ERK phosphorylation analysis, Klf5 re-expression (specificity comparison with Klf2, Klf4), Spred1 expression analysis, EpiSC reprogramming assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with rescue and paralog specificity test plus downstream target analysis, single lab","pmids":["30452437"],"is_preprint":false},{"year":2014,"finding":"Simultaneous knockdown of KLF5 and Fli1 in dermal fibroblasts synergistically enhances connective tissue growth factor expression; double heterozygous Klf5/Fli1 mice spontaneously develop all three cardinal features of systemic sclerosis (fibrosis, vasculopathy, autoantibody production), establishing epigenetic co-downregulation of these two transcription factors as a central pathogenic event.","method":"siRNA double knockdown in primary fibroblasts, Klf5+/- Fli1+/- double heterozygous mouse model, histological/immunological phenotyping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-heterozygous mouse spontaneous disease model plus cellular knockdown epistasis, key mechanistic finding","pmids":["25504335"],"is_preprint":false}],"current_model":"KLF5 is a nuclear zinc-finger transcription factor that binds GC-rich promoter elements to activate or repress target genes (including PDGF-A, TGF-β, PPARα, NOX4, COX2, SMemb/NMHC-B, FYN, RAD51, eIF5a, and others) and whose activity is tightly controlled by a network of post-translational modifications—phosphorylation (by PKC/GSK3β, promoting Fbw7-mediated ubiquitination and degradation), ubiquitination (by E3 ligases WWP1 and Fbw7, reversed by DUBs BAP1, USP3), acetylation at K369 (by p300/CBP, reversed by HDAC1/2, switching its proliferative to anti-proliferative function and affecting its stability and partner binding), and arginine methylation at R57/R41 by PRMT5 (antagonizing GSK3β-phosphorylation to stabilize KLF5)—while protein stability is also regulated by interacting partners YAP, TAZ, and α-Catulin that compete with WWP1 for the KLF5 PY motif; upstream, KLF5 expression is induced by angiotensin II, FOXO1, Egr-1/MAPK, and Wnt-1 (via noncanonical PKC-dependent pathway), and it interacts physically with RAR, CBP/EP300, AR, YAP1/TEAD, and other co-regulators to control cardiovascular remodeling, intestinal stem cell integrity, alveolar epithelial fate, prostate progenitor differentiation, skeletal muscle atrophy, and cancer cell proliferation/stemness."},"narrative":{"mechanistic_narrative":"KLF5 (originally BTEB2/IKLF) is a GC-box-binding zinc-finger transcription factor that programs cell proliferation, differentiation, and lineage fidelity across cardiovascular, epithelial, embryonic, and cancer contexts, acting through three C-terminal zinc fingers that bind Sp1-like GC-rich elements and a proline-rich N-terminal activation domain that contacts the basal transcription machinery (TFIIB, TFIIEβ, TFIIFβ, TBP) [PMID:8479902, PMID:9089417]. At target promoters KLF5 directly activates or represses genes spanning vascular and metabolic remodeling—PDGF-A, TGF-β, SMemb/NMHC-B, the lipid-oxidation regulator PPARα, the oxidant source NOX4, and the mitochondrial-protective factor eIF5a—and its loss drives cardiac dysfunction, vascular senescence, and aneurysm phenotypes in tissue-specific knockout mice [PMID:10417400, PMID:12101409, PMID:26574507, PMID:33539225, PMID:32817651]. The same factor controls cell-fate decisions: it establishes bipotential ICM/trophectoderm fate in early embryos, maintains intestinal Lgr5+ stem cells and is required for β-catenin-driven oncogenesis, enforces AT2-to-AT1 alveolar differentiation, and governs prostate basal/luminal balance [PMID:34758315, PMID:24626089, PMID:35803279, PMID:32081850]. In cancer, KLF5 promotes proliferation, migration, and stemness by activating targets including FYN, COX2, and RAD51 and by nucleating an enhancer machine in which it recruits the CBP/EP300 acetyltransferase complex together with TP63 and YAP1 to deposit H3K27ac, recruit BRD4, and drive Pol II elongation through 3D chromatin loops [PMID:26786295, PMID:36923542, PMID:37702443, PMID:33115806]. KLF5 abundance is set by a dense post-translational network: GSK3β-primed phosphodegrons recruit the E3 ligase FBW7 for degradation, WWP1 ubiquitinates the PY motif, and these destabilizing events are opposed by deubiquitinases BAP1 and USP3, by PY-motif competitors YAP, TAZ, and α-Catulin, and by PRMT5-catalyzed arginine methylation that antagonizes GSK3β phosphorylation [PMID:24921010, PMID:26419610, PMID:31624151, PMID:22045023, PMID:22632819, PMID:35154481, PMID:33972717]. Acetylation at K369 by the CBP/EP300 axis, reversed by HDAC1/2, additionally toggles KLF5 between proliferative and differentiative outputs and modulates its stability by controlling BAP1 binding [PMID:29679567, PMID:32081850, PMID:35342356]. WWP2-mediated monoubiquitination instead activates rather than degrades KLF5 to drive odontoblast differentiation genes, illustrating that distinct ubiquitin marks specify opposite functional fates [PMID:33164644].","teleology":[{"year":1993,"claim":"Established the founding biochemical identity of KLF5 as a sequence-specific GC-box transcriptional activator, defining its DNA-binding and transactivation modules.","evidence":"cDNA cloning with recombinant DNA-binding (EMSA), reporter, and GAL4 fusion transactivation assays","pmids":["8479902"],"confidence":"High","gaps":["Physiological target genes not yet identified","No cellular or in vivo context"]},{"year":1997,"claim":"Localized the activation domain to a short hydrophobic proline/alanine-rich region and showed direct contact with the basal transcription machinery, explaining how KLF5 stimulates transcription.","evidence":"In vitro transcription with purified protein, deletion mutagenesis, pulldown with TFIIB/TFIIEβ/TFIIFβ/TBP","pmids":["9089417"],"confidence":"High","gaps":["Interactions tested in vitro only","No coactivator context beyond basal factors"]},{"year":1999,"claim":"Connected KLF5 to vascular smooth muscle gene programs and defined its upstream induction by MAPK/Egr-1, placing it within stress-response signaling in the vasculature.","evidence":"EMSA/supershift, GST-DNA binding, reporter mutagenesis on SMemb/SE1 and the Egr-1 site of the KLF5 promoter, MAPK inhibition","pmids":["10417400","10532946"],"confidence":"High","gaps":["In vivo requirement not yet tested","Whether repression vs activation is context-dependent unresolved"]},{"year":1999,"claim":"Demonstrated KLF5 can act as a repressor on a CAAT/GT-box target and confirmed nuclear localization, broadening its regulatory repertoire beyond activation.","evidence":"DNase I footprinting, EMSA, GFP localization, reporter assay in endometrial carcinoma cells","pmids":["10572182"],"confidence":"High","gaps":["Determinants of activation vs repression not defined"]},{"year":2002,"claim":"Provided the first in vivo genetic evidence that KLF5 drives cardiovascular remodeling through PDGF-A/TGF-β induction and is modulated by RAR, with homozygous loss being embryonic lethal.","evidence":"Heterozygous Klf5 knockout mice, ChIP on PDGF-A, KLF5–RAR co-IP, RAR-ligand pharmacology","pmids":["12101409"],"confidence":"High","gaps":["Cell-type-specific contributions not dissected","Mechanism of RAR-dependent modulation incomplete"]},{"year":2003,"claim":"Showed CBP coactivation of KLF5 requires PKC-dependent phosphorylation, linking signal-induced phosphorylation to coactivator recruitment.","evidence":"GAL4 transactivation, co-IP, GST pulldown, PKC-site mutagenesis, kinase inhibition","pmids":["12682370"],"confidence":"High","gaps":["Responsible PKC isoform and in vivo phosphosite not defined","CBP HAT does not acetylate KLF5 in vitro—acetylating enzyme left open"]},{"year":2003,"claim":"Extended KLF5 promoter occupancy to an endogenous immune locus (TCR Dbeta1), confirming functional chromatin binding in a distinct lineage.","evidence":"Yeast one-hybrid, supershift EMSA, ChIP, dominant-negative reporter assay","pmids":["12576331"],"confidence":"High","gaps":["Physiological role in T-cell development not tested in vivo"]},{"year":2004,"claim":"Revealed that oncogenic Ras switches KLF5 from a cyclin D1-inducing growth promoter to a growth suppressor and destabilizes the protein, introducing the theme of context-dependent KLF5 function.","evidence":"Isogenic Ras-transformed intestinal epithelial cells, colony formation, cyclin D1 reporter, protein stability analysis","pmids":["14726538"],"confidence":"Medium","gaps":["Molecular basis of the functional switch undefined","Single cell-line system"]},{"year":2014,"claim":"Defined the core degradation machinery for KLF5: GSK3β-phosphorylated CPD degrons recruit FBW7 for ubiquitination, establishing the central phospho-degradation axis.","evidence":"Ubiquitination assay, co-IP, CPD mutagenesis, GSK3β involvement (review integrating primary data)","pmids":["24921010"],"confidence":"Medium","gaps":["Synthesized from prior primary work","Kinase priming hierarchy not fully resolved"]},{"year":2014,"claim":"Placed KLF5 within intestinal stem cell maintenance and made it genetically required for β-catenin-driven tumorigenesis, and separately implicated it (with Fli1) in systemic sclerosis pathogenesis.","evidence":"Inducible Lgr5-Klf5 KO with oncogenic β-catenin epistasis; Klf5/Fli1 double-heterozygous mouse fibrosis model","pmids":["24626089","25504335"],"confidence":"High","gaps":["Direct transcriptional targets in each setting not enumerated","Relationship between stem-cell and disease roles unclear"]},{"year":2012,"claim":"Identified Hippo effectors YAP and TAZ as KLF5 stabilizers that competitively block WWP1 at the PY motif, coupling Hippo signaling to KLF5 protein levels and target gene output.","evidence":"Co-IP, ubiquitination assays, WW-domain mutants, siRNA, xenografts","pmids":["22045023","22632819"],"confidence":"High","gaps":["Relative contributions of YAP vs TAZ across tissues not resolved","Stoichiometry of competition with WWP1 undefined"]},{"year":2015,"claim":"Showed KLF5 directly drives cardiac PPARα and identified BAP1 as a stabilizing deubiquitinase, linking KLF5 to fatty-acid oxidation metabolism and to enzymatic ubiquitin removal.","evidence":"Cardiomyocyte-specific KO with metabolic phenotyping and ChIP; genome-wide DUB screen, DUB assay, in vivo rescue","pmids":["26574507","26419610"],"confidence":"High","gaps":["c-Jun competition mechanism at the PPARα promoter incompletely mapped","BAP1/HCF-1 complex stoichiometry undefined"]},{"year":2017,"claim":"Established KLF5 as a transcriptional driver of macrophage podosome formation and migration through Myo9b/RhoA, broadening its role into immune-cell motility and aneurysm pathology.","evidence":"Myeloid-specific KO, Myo9b reporter, migration imaging, RhoA-GTP pulldown","pmids":["28115390"],"confidence":"High","gaps":["Direct vs indirect RhoA regulation not fully separated"]},{"year":2018,"claim":"Defined acetylation/deacetylation at K369 as a stability and function switch: HDAC1/2-mediated deacetylation promotes degradation while acetyl-mimic blocks it, and showed KLF5 suppresses ERK via Spred1 in ESCs.","evidence":"HDAC1/2 siRNA, K369Q/K369R mutagenesis, CHX chase, MG132, co-IP; Klf5-KO ESCs with paralog-specific rescue and Spred1 analysis; FYN transactivation in bladder cancer","pmids":["29679567","30452437","26786295"],"confidence":"Medium","gaps":["Enzyme depositing K369 acetylation not identified here","Single-lab stability data"]},{"year":2019,"claim":"Added USP3 as a second stabilizing deubiquitinase, reinforcing that KLF5 levels are set by opposing ligase/DUB activities.","evidence":"Genome-wide DUB screen, co-IP, DUB assay, knockdown-rescue, in vivo tumorigenesis","pmids":["31624151"],"confidence":"High","gaps":["Substrate-site specificity of USP3 vs BAP1 undefined"]},{"year":2020,"claim":"Multiple in vivo studies cemented KLF5 as a tissue lineage and metabolic determinant—alveolar AT1 fidelity, prostate basal progenitor maintenance via K369 acetylation, skeletal-muscle atrophy, and FOXO1→KLF5→NOX4 oxidative injury—and revealed a KLF5→eIF5a→Mfn1 axis preserving mitochondrial integrity.","evidence":"Cell-type-specific KO and acetylation knock-in mice, organoids, ChIP, ATAC-seq, AAV rescue, metabolic/ROS readouts","pmids":["35803279","32081850","34426497","33539225","32817651"],"confidence":"High","gaps":["Upstream selectivity directing KLF5 to opposing differentiation outcomes unclear","How a single factor coordinates such divergent tissue programs unresolved"]},{"year":2020,"claim":"Resolved how KLF5 amplifies transcription mechanistically: it recruits the CBP/EP300 complex with TP63 and YAP1 to deposit H3K27ac, recruit BRD4, and aggregate distal binding events into 3D loops driving Pol II elongation.","evidence":"IP-MS interactome, HiChIP, H3K27ac/BRD4 ChIP-seq, PROTAC BRD4 degradation, dependency screen","pmids":["33115806"],"confidence":"High","gaps":["Whether this enhancer-machine mode operates outside cancer chromatin untested"]},{"year":2021,"claim":"Defined arginine methylation as a stabilizing PTM—PRMT5 dimethylates KLF5 (R57 in breast cancer, R41 in lung) to antagonize GSK3β phosphorylation and FBW7 degradation—and clarified acetylation–ubiquitination crosstalk via reduced BAP1 binding.","evidence":"In vitro methylation assays, R57/R41 mutagenesis, PRMT5 inhibitors, PTM crosstalk and BAP1-binding analysis, xenografts","pmids":["33972717","37461162","35342356"],"confidence":"Medium","gaps":["Discrepant methylated residue (R57 vs R41) across tissues not reconciled","Some crosstalk data from single labs"]},{"year":2021,"claim":"Detailed KLF5's combinatorial roles with other factors: opposing AR on chromatin to set basal/luminal prostate programs, partnering YB-1 in basal-like breast cancer, repressing COX2/PGE2 to shape anti-tumor immunity, and dual ICM/TE fate induction in embryos.","evidence":"Chromatin co-IP, ChIP-seq, RNA-seq, mRNA-stability assays, ChIP-seq embryo targets, KO/chimera epistasis, immune profiling","pmids":["34737261","35022570","36923542","34758315"],"confidence":"Medium","gaps":["Mechanism of KLF5-AR antagonism on shared loci incomplete","COX2 axis tested in limited tumor models"]},{"year":2022,"claim":"Showed ubiquitin-mark identity determines outcome: WWP2 monoubiquitination of KLF5 transactivates rather than degrades it to drive odontoblast differentiation, and α-Catulin competes with WWP1 to stabilize KLF5 in lung cancer stemness.","evidence":"Ubiquitination assays with WWP2 C838A and KLF5 lysine/PY2 mutants, differentiation assays; yeast two-hybrid, co-IP, CHX chase, ILK inhibition","pmids":["33164644","35154481"],"confidence":"Medium","gaps":["How mono- vs poly-ubiquitin marks are selected at shared lysines unclear","Single-lab data for each interaction"]},{"year":2023,"claim":"Expanded KLF5's cancer transcriptional partnerships—SRC-phospho-YAP1/TEAD complexes driving Hippo-independent stemness, and an EHF/ELF3-KLF5 complex activating RAD51 to bolster homologous recombination repair.","evidence":"Co-IP, SRC inhibition, phospho-YAP1 mutants, ChIP, super-enhancer analysis, HRR functional assay","pmids":["36633714","37702443"],"confidence":"Medium","gaps":["Direct vs indirect assembly of these complexes not fully resolved","Single-lab findings"]},{"year":2024,"claim":"Linked KLF5 to non-cell-autonomous tumor signaling and chromatin metabolism: deacetylated KLF5 downstream of PTEN loss drives a TNF-α/CAF/FGF9/FGFR1 paracrine loop, while lactate-driven H3K14 lactylation promotes KLF5 expression to repress E-cadherin and drive EMT in diabetic kidney disease.","evidence":"Acetylation knock-in mouse with co-culture and pharmacology; ChIP-seq H3K14la, ChIP on cdh1, nephron-specific knockdown","pmids":["38781024","38925041"],"confidence":"Medium","gaps":["Generalizability of the paracrine loop beyond PTEN-null prostate cancer untested","Lactylation→KLF5 chromatin mechanism single-study"]},{"year":null,"claim":"It remains unresolved how a single GC-box factor is directed toward opposite outcomes—proliferation vs differentiation, activation vs repression—across tissues, and how the combinatorial PTM code (phosphorylation, ubiquitination type, acetylation, methylation) is integrated at the level of partner choice and target selection.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model linking PTM state to partner/target selection","Structural basis of PY-motif competition among YAP/TAZ/α-Catulin/WWP1 undefined","Reconciliation of opposing tissue functions absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,14,18,23,26]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,4,8]},{"term_id":"GO:0140223","term_label":"general transcription initiation factor activity","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[38]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6,14,18,38]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[26,29,20]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[12,13,22,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,31,40]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[39,41,18]}],"complexes":["YAP1/TEAD-KLF5 transcriptional complex","KLF5-EHF-ELF3 complex","BAP1/HCF-1 complex","KLF5-CBP/EP300 acetyltransferase complex"],"partners":["YAP1","TAZ","WWP1","FBXW7","BAP1","PRMT5","EP300","AR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13887","full_name":"Krueppel-like factor 5","aliases":["Basic transcription element-binding protein 2","BTE-binding protein 2","Colon krueppel-like factor","GC-box-binding protein 2","Intestinal-enriched krueppel-like factor","Transcription factor BTEB2"],"length_aa":457,"mass_kda":50.8,"function":"Transcription factor that binds to GC box promoter elements. Activates the transcription of these genes","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13887/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KLF5","classification":"Not Classified","n_dependent_lines":344,"n_total_lines":1208,"dependency_fraction":0.2847682119205298},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KLF5","total_profiled":1310},"omim":[{"mim_id":"616841","title":"ZINC FINGER PROTEIN 468; ZNF468","url":"https://www.omim.org/entry/616841"},{"mim_id":"607343","title":"SAL-LIKE 4; SALL4","url":"https://www.omim.org/entry/607343"},{"mim_id":"602903","title":"KLF TRANSCRIPTION FACTOR 5; KLF5","url":"https://www.omim.org/entry/602903"},{"mim_id":"114550","title":"HEPATOCELLULAR CARCINOMA","url":"https://www.omim.org/entry/114550"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":226.7},{"tissue":"skin 1","ntpm":221.8}],"url":"https://www.proteinatlas.org/search/KLF5"},"hgnc":{"alias_symbol":["IKLF","CKLF"],"prev_symbol":["BTEB2"]},"alphafold":{"accession":"Q13887","domains":[{"cath_id":"3.30.160","chopping":"367-400","consensus_level":"medium","plddt":75.5044,"start":367,"end":400}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13887","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13887-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13887-F1-predicted_aligned_error_v6.png","plddt_mean":46.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KLF5","jax_strain_url":"https://www.jax.org/strain/search?query=KLF5"},"sequence":{"accession":"Q13887","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13887.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13887/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13887"}},"corpus_meta":[{"pmid":"12101409","id":"PMC_12101409","title":"Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12101409","citation_count":334,"is_preprint":false},{"pmid":"19448973","id":"PMC_19448973","title":"Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases.","date":"2009","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/19448973","citation_count":231,"is_preprint":false},{"pmid":"8479902","id":"PMC_8479902","title":"cDNA cloning and transcriptional properties of a novel GC box-binding protein, BTEB2.","date":"1993","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8479902","citation_count":180,"is_preprint":false},{"pmid":"26419610","id":"PMC_26419610","title":"BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26419610","citation_count":180,"is_preprint":false},{"pmid":"16357509","id":"PMC_16357509","title":"KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells.","date":"2005","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16357509","citation_count":164,"is_preprint":false},{"pmid":"16184550","id":"PMC_16184550","title":"KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16184550","citation_count":131,"is_preprint":false},{"pmid":"33539225","id":"PMC_33539225","title":"KLF5 Is Induced by FOXO1 and Causes Oxidative Stress and Diabetic Cardiomyopathy.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/33539225","citation_count":126,"is_preprint":false},{"pmid":"10417400","id":"PMC_10417400","title":"BTEB2, a Krüppel-like transcription factor, regulates expression of the SMemb/Nonmuscle myosin heavy chain B (SMemb/NMHC-B) gene.","date":"1999","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10417400","citation_count":117,"is_preprint":false},{"pmid":"38925041","id":"PMC_38925041","title":"Lactate drives epithelial-mesenchymal transition in diabetic kidney disease via the H3K14la/KLF5 pathway.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38925041","citation_count":116,"is_preprint":false},{"pmid":"25504335","id":"PMC_25504335","title":"Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25504335","citation_count":115,"is_preprint":false},{"pmid":"22632819","id":"PMC_22632819","title":"YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22632819","citation_count":114,"is_preprint":false},{"pmid":"33811715","id":"PMC_33811715","title":"The roles and regulation of the KLF5 transcription factor in cancers.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33811715","citation_count":112,"is_preprint":false},{"pmid":"14726538","id":"PMC_14726538","title":"Intestinal tumor progression is associated with altered function of KLF5.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14726538","citation_count":106,"is_preprint":false},{"pmid":"26574507","id":"PMC_26574507","title":"Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function.","date":"2015","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/26574507","citation_count":101,"is_preprint":false},{"pmid":"24770696","id":"PMC_24770696","title":"Klf4 and Klf5 differentially inhibit mesoderm and endoderm differentiation in embryonic stem cells.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24770696","citation_count":99,"is_preprint":false},{"pmid":"16102021","id":"PMC_16102021","title":"Significance of the transcription factor KLF5 in cardiovascular remodeling.","date":"2005","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/16102021","citation_count":86,"is_preprint":false},{"pmid":"22045023","id":"PMC_22045023","title":"TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22045023","citation_count":81,"is_preprint":false},{"pmid":"10532946","id":"PMC_10532946","title":"Transcriptional activation of the zinc finger transcription factor BTEB2 gene by Egr-1 through mitogen-activated protein kinase pathways in vascular smooth muscle cells.","date":"1999","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10532946","citation_count":78,"is_preprint":false},{"pmid":"10767086","id":"PMC_10767086","title":"Developmental expression of the mouse gene coding for the Krüppel-like transcription factor KLF5.","date":"2000","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/10767086","citation_count":71,"is_preprint":false},{"pmid":"25732792","id":"PMC_25732792","title":"Targeting Krüppel-like factor 5 (KLF5) for cancer therapy.","date":"2015","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25732792","citation_count":69,"is_preprint":false},{"pmid":"24626089","id":"PMC_24626089","title":"KLF5 regulates the integrity and oncogenicity of intestinal stem cells.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24626089","citation_count":69,"is_preprint":false},{"pmid":"12682370","id":"PMC_12682370","title":"Phosphorylation of Kruppel-like factor 5 (KLF5/IKLF) at the CBP interaction region enhances its transactivation function.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12682370","citation_count":67,"is_preprint":false},{"pmid":"35022570","id":"PMC_35022570","title":"YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer.","date":"2022","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/35022570","citation_count":65,"is_preprint":false},{"pmid":"32817651","id":"PMC_32817651","title":"Klf5 down-regulation induces vascular senescence through eIF5a depletion and mitochondrial fission.","date":"2020","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/32817651","citation_count":65,"is_preprint":false},{"pmid":"10572182","id":"PMC_10572182","title":"Isolation and characterization of a gene encoding human Kruppel-like factor 5 (IKLF): binding to the CAAT/GT box of the mouse lactoferrin gene promoter.","date":"1999","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10572182","citation_count":61,"is_preprint":false},{"pmid":"29782853","id":"PMC_29782853","title":"Cholesterol promotes the migration and invasion of renal carcinoma cells by regulating the KLF5/miR-27a/FBXW7 pathway.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29782853","citation_count":60,"is_preprint":false},{"pmid":"11134343","id":"PMC_11134343","title":"Identification of a mouse homolog of the human BTEB2 transcription factor as a beta-catenin-independent Wnt-1-responsive gene.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11134343","citation_count":57,"is_preprint":false},{"pmid":"31624151","id":"PMC_31624151","title":"USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31624151","citation_count":56,"is_preprint":false},{"pmid":"26702149","id":"PMC_26702149","title":"KLF5 mediates vascular remodeling via HIF-1α in hypoxic pulmonary hypertension.","date":"2015","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26702149","citation_count":55,"is_preprint":false},{"pmid":"33972717","id":"PMC_33972717","title":"Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/33972717","citation_count":54,"is_preprint":false},{"pmid":"30675287","id":"PMC_30675287","title":"miR-21 promotes cell migration and invasion of hepatocellular carcinoma by targeting KLF5.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30675287","citation_count":52,"is_preprint":false},{"pmid":"25051115","id":"PMC_25051115","title":"KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small cell lung cancer cells via HIF-1α.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25051115","citation_count":50,"is_preprint":false},{"pmid":"28115390","id":"PMC_28115390","title":"Inhibition of KLF5-Myo9b-RhoA Pathway-Mediated Podosome Formation in Macrophages Ameliorates Abdominal Aortic Aneurysm.","date":"2017","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/28115390","citation_count":48,"is_preprint":false},{"pmid":"34466790","id":"PMC_34466790","title":"YAP regulates alveolar epithelial cell differentiation and AGER via NFIB/KLF5/NKX2-1.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34466790","citation_count":46,"is_preprint":false},{"pmid":"24323942","id":"PMC_24323942","title":"The double life of KLF5: Opposing roles in regulation of gene-expression, cellular function, and transformation.","date":"2013","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/24323942","citation_count":45,"is_preprint":false},{"pmid":"33115806","id":"PMC_33115806","title":"Chromatin Looping Shapes KLF5-Dependent Transcriptional Programs in Human Epithelial Cancers.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33115806","citation_count":42,"is_preprint":false},{"pmid":"28437471","id":"PMC_28437471","title":"miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28437471","citation_count":41,"is_preprint":false},{"pmid":"37702443","id":"PMC_37702443","title":"KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37702443","citation_count":38,"is_preprint":false},{"pmid":"31360115","id":"PMC_31360115","title":"Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers.","date":"2019","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31360115","citation_count":38,"is_preprint":false},{"pmid":"34653523","id":"PMC_34653523","title":"Krüppel-like factor (KLF)5: An emerging foe of cardiovascular health.","date":"2021","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/34653523","citation_count":37,"is_preprint":false},{"pmid":"19268913","id":"PMC_19268913","title":"Spatial and temporal expression of KLF4 and KLF5 during murine tooth development.","date":"2009","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/19268913","citation_count":35,"is_preprint":false},{"pmid":"30478887","id":"PMC_30478887","title":"EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.","date":"2019","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30478887","citation_count":35,"is_preprint":false},{"pmid":"34426497","id":"PMC_34426497","title":"Identification of a KLF5-dependent program and drug development for skeletal muscle atrophy.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34426497","citation_count":33,"is_preprint":false},{"pmid":"34737261","id":"PMC_34737261","title":"Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34737261","citation_count":33,"is_preprint":false},{"pmid":"32081850","id":"PMC_32081850","title":"Klf5 acetylation regulates luminal differentiation of basal progenitors in prostate development and regeneration.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32081850","citation_count":33,"is_preprint":false},{"pmid":"34758315","id":"PMC_34758315","title":"Klf5 establishes bi-potential cell fate by dual regulation of ICM and TE specification genes.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34758315","citation_count":32,"is_preprint":false},{"pmid":"9089417","id":"PMC_9089417","title":"Transcriptional activation domain of human BTEB2, a GC box-binding factor.","date":"1997","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9089417","citation_count":31,"is_preprint":false},{"pmid":"25687411","id":"PMC_25687411","title":"KLF5 regulates infection- and inflammation-induced pro-labour mediators in human myometrium.","date":"2015","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25687411","citation_count":31,"is_preprint":false},{"pmid":"31178864","id":"PMC_31178864","title":"Excessive miR-152-3p Results in Increased BAFF Expression in SLE B-Cells by Inhibiting the KLF5 Expression.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31178864","citation_count":31,"is_preprint":false},{"pmid":"36923542","id":"PMC_36923542","title":"KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/36923542","citation_count":30,"is_preprint":false},{"pmid":"12576331","id":"PMC_12576331","title":"Regulation of T-cell receptor D beta 1 promoter by KLF5 through reiterated GC-rich motifs.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12576331","citation_count":30,"is_preprint":false},{"pmid":"33020901","id":"PMC_33020901","title":"Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression.","date":"2020","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33020901","citation_count":30,"is_preprint":false},{"pmid":"15098654","id":"PMC_15098654","title":"KLF5/BTEB2, a Krüppel-like zinc-finger type transcription factor, mediates both smooth muscle cell activation and cardiac hypertrophy.","date":"2003","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/15098654","citation_count":29,"is_preprint":false},{"pmid":"24584857","id":"PMC_24584857","title":"CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24584857","citation_count":29,"is_preprint":false},{"pmid":"26786295","id":"PMC_26786295","title":"KLF5 promotes cell migration by up-regulating FYN in bladder cancer cells.","date":"2016","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/26786295","citation_count":29,"is_preprint":false},{"pmid":"34165154","id":"PMC_34165154","title":"KLF5/LINC00346/miR‑148a‑3p axis regulates inflammation and endothelial cell injury in atherosclerosis.","date":"2021","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34165154","citation_count":28,"is_preprint":false},{"pmid":"29074464","id":"PMC_29074464","title":"Regulatory crosstalk between KLF5, miR-29a and Fbw7/CDC4 cooperatively promotes atherosclerotic development.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29074464","citation_count":28,"is_preprint":false},{"pmid":"34052325","id":"PMC_34052325","title":"KLF5-induced lncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34052325","citation_count":28,"is_preprint":false},{"pmid":"38515158","id":"PMC_38515158","title":"Acetyl-CoA synthetase 2 induces pyroptosis and inflammation of renal epithelial tubular cells in sepsis-induced acute kidney injury by upregulating the KLF5/NF-κB pathway.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38515158","citation_count":26,"is_preprint":false},{"pmid":"33516665","id":"PMC_33516665","title":"BAP1 antagonizes WWP1-mediated transcription factor KLF5 ubiquitination and inhibits autophagy to promote melanoma progression.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33516665","citation_count":25,"is_preprint":false},{"pmid":"35803279","id":"PMC_35803279","title":"Klf5 defines alveolar epithelial type 1 cell lineage commitment during lung development and regeneration.","date":"2022","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/35803279","citation_count":24,"is_preprint":false},{"pmid":"36633714","id":"PMC_36633714","title":"Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/36633714","citation_count":24,"is_preprint":false},{"pmid":"35342356","id":"PMC_35342356","title":"Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35342356","citation_count":24,"is_preprint":false},{"pmid":"37063424","id":"PMC_37063424","title":"Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37063424","citation_count":23,"is_preprint":false},{"pmid":"32373958","id":"PMC_32373958","title":"KLF5 promotes proliferation in gastric cancer via regulating p21 and CDK4.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32373958","citation_count":22,"is_preprint":false},{"pmid":"30963560","id":"PMC_30963560","title":"MKK7 transcription positively or negatively regulated by SP1 and KLF5 depends on HDAC4 activity in glioma.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30963560","citation_count":22,"is_preprint":false},{"pmid":"30226614","id":"PMC_30226614","title":"KLF5 promotes the tumorigenesis and metastatic potential of thyroid cancer cells through the NF-κB signaling pathway.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30226614","citation_count":22,"is_preprint":false},{"pmid":"33690159","id":"PMC_33690159","title":"KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33690159","citation_count":20,"is_preprint":false},{"pmid":"34548487","id":"PMC_34548487","title":"KLF5 activates lncRNA DANCR and inhibits cancer cell autophagy accelerating gastric cancer progression.","date":"2021","source":"NPJ genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34548487","citation_count":20,"is_preprint":false},{"pmid":"30685841","id":"PMC_30685841","title":"CDX1/2 and KLF5 Expression and Epigenetic Modulation of Sonic Hedgehog Signaling in Gastric Adenocarcinoma.","date":"2019","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/30685841","citation_count":20,"is_preprint":false},{"pmid":"33164644","id":"PMC_33164644","title":"WWP2 Promotes Odontoblastic Differentiation by Monoubiquitinating KLF5.","date":"2020","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/33164644","citation_count":20,"is_preprint":false},{"pmid":"35154481","id":"PMC_35154481","title":"α-Catulin promotes cancer stemness by antagonizing WWP1-mediated KLF5 degradation in lung cancer.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35154481","citation_count":20,"is_preprint":false},{"pmid":"33842324","id":"PMC_33842324","title":"A Positive Feedback Loop of Long Noncoding RNA LINC00152 and KLF5 Facilitates Breast Cancer Growth.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33842324","citation_count":20,"is_preprint":false},{"pmid":"26451280","id":"PMC_26451280","title":"The transient expression of Klf4 and Klf5 during adipogenesis depends on GSK3β activity.","date":"2015","source":"Adipocyte","url":"https://pubmed.ncbi.nlm.nih.gov/26451280","citation_count":20,"is_preprint":false},{"pmid":"30322616","id":"PMC_30322616","title":"miR-448-3p controls intracranial aneurysm by regulating KLF5 expression.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30322616","citation_count":20,"is_preprint":false},{"pmid":"38781024","id":"PMC_38781024","title":"Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38781024","citation_count":19,"is_preprint":false},{"pmid":"40016182","id":"PMC_40016182","title":"Porphyromonas gingivalis potentiates stem-like properties of oral squamous cell carcinoma by modulating SCD1-dependent lipid synthesis via NOD1/KLF5 axis.","date":"2025","source":"International journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/40016182","citation_count":19,"is_preprint":false},{"pmid":"36810084","id":"PMC_36810084","title":"Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer.","date":"2023","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36810084","citation_count":19,"is_preprint":false},{"pmid":"29916536","id":"PMC_29916536","title":"miR‑590‑5p suppresses osteosarcoma cell proliferation and invasion via targeting KLF5.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29916536","citation_count":19,"is_preprint":false},{"pmid":"29679567","id":"PMC_29679567","title":"HDAC-mediated deacetylation of KLF5 associates with its proteasomal degradation.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29679567","citation_count":19,"is_preprint":false},{"pmid":"34403009","id":"PMC_34403009","title":"LINC01123 promotes cell proliferation and migration via regulating miR-1277-5p/KLF5 axis in ox-LDL-induced vascular smooth muscle cells.","date":"2021","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/34403009","citation_count":19,"is_preprint":false},{"pmid":"34004248","id":"PMC_34004248","title":"MicroRNA-146a-3p/HDAC1/KLF5/IKBα signal axis modulates plaque formation of atherosclerosis mice.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34004248","citation_count":19,"is_preprint":false},{"pmid":"33981482","id":"PMC_33981482","title":"Interfering microRNA-410 attenuates atherosclerosis via the HDAC1/KLF5/IKBα/NF-κB axis.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33981482","citation_count":19,"is_preprint":false},{"pmid":"34367275","id":"PMC_34367275","title":"The Partial Role of KLF4 and KLF5 in Gastrointestinal Tumors.","date":"2021","source":"Gastroenterology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/34367275","citation_count":18,"is_preprint":false},{"pmid":"33294297","id":"PMC_33294297","title":"BTEB2-Activated lncRNA TSPEAR-AS2 Drives GC Progression through Suppressing GJA1 Expression and Upregulating CLDN4 Expression.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33294297","citation_count":18,"is_preprint":false},{"pmid":"33827480","id":"PMC_33827480","title":"KLF5-mediated Eppk1 expression promotes cell proliferation in cervical cancer via the p38 signaling pathway.","date":"2021","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33827480","citation_count":18,"is_preprint":false},{"pmid":"32641593","id":"PMC_32641593","title":"KLF5 regulates chicken skeletal muscle atrophy via the canonical Wnt/β-catenin signaling pathway.","date":"2020","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/32641593","citation_count":18,"is_preprint":false},{"pmid":"33923166","id":"PMC_33923166","title":"KLF5 Is Activated by Gene Amplification in Gastric Cancer and Is Essential for Gastric Cell Proliferation.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33923166","citation_count":18,"is_preprint":false},{"pmid":"33971492","id":"PMC_33971492","title":"CircATRNL1 protects against osteoarthritis by targeting miR-153-3p and KLF5.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33971492","citation_count":18,"is_preprint":false},{"pmid":"31049798","id":"PMC_31049798","title":"Hyperinsulinemia-induced KLF5 mediates endothelial angiogenic dysfunction in diabetic endothelial cells.","date":"2019","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/31049798","citation_count":17,"is_preprint":false},{"pmid":"14557694","id":"PMC_14557694","title":"Smooth muscle cell outgrowth from coronary atherectomy specimens in vitro is associated with less time to restenosis and expression of a key Transcription factor KLF5/BTEB2.","date":"2003","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/14557694","citation_count":17,"is_preprint":false},{"pmid":"34530084","id":"PMC_34530084","title":"RNA-seq analysis reveals the positive role of KLF5 in the differentiation of subcutaneous adipocyte in goats.","date":"2021","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/34530084","citation_count":16,"is_preprint":false},{"pmid":"30452437","id":"PMC_30452437","title":"Klf5 suppresses ERK signaling in mouse pluripotent stem cells.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30452437","citation_count":16,"is_preprint":false},{"pmid":"31857253","id":"PMC_31857253","title":"Identification and functional characterization of KLF5 as a novel disease gene responsible for familial dilated cardiomyopathy.","date":"2019","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31857253","citation_count":16,"is_preprint":false},{"pmid":"30106142","id":"PMC_30106142","title":"Overexpression of KLF5 inhibits puromycin‑induced apoptosis of podocytes.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30106142","citation_count":16,"is_preprint":false},{"pmid":"38414248","id":"PMC_38414248","title":"Activation of the YAP/KLF5 transcriptional cascade in renal tubular cells aggravates kidney injury.","date":"2024","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38414248","citation_count":15,"is_preprint":false},{"pmid":"24921010","id":"PMC_24921010","title":"FBW7-mediated ubiquitination and degradation of KLF5.","date":"2014","source":"World journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24921010","citation_count":15,"is_preprint":false},{"pmid":"33904383","id":"PMC_33904383","title":"MicroRNA-140-3p alleviates intervertebral disc degeneration via KLF5/N-cadherin/MDM2/Slug axis.","date":"2021","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/33904383","citation_count":15,"is_preprint":false},{"pmid":"37461162","id":"PMC_37461162","title":"PRMT5 activates KLF5 by methylation to facilitate lung cancer.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37461162","citation_count":14,"is_preprint":false},{"pmid":"33529461","id":"PMC_33529461","title":"BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1.","date":"2021","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/33529461","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50573,"output_tokens":11821,"usd":0.164517,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22811,"output_tokens":7288,"usd":0.148127,"stage2_stop_reason":"end_turn"},"total_usd":0.312644,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"KLF5 (BTEB2) encodes a GC box-binding protein with three C-terminal zinc finger motifs that binds DNA with specificity similar to Sp1 and activates transcription through a proline/serine/threonine/alanine-rich N-terminal region; recombinant BTEB2 expressed in E. coli showed sequence-specific DNA-binding activity, and cotransfection experiments demonstrated transcriptional activation of GC box-containing reporters.\",\n      \"method\": \"cDNA cloning, recombinant protein DNA-binding assay, cotransfection reporter assay, GAL4 fusion transactivation assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro DNA-binding reconstitution plus multiple orthogonal functional assays (EMSA, reporter, GAL4 fusion) in a single foundational study\",\n      \"pmids\": [\"8479902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The transcriptional activation domain of KLF5 (BTEB2) resides in a ~10-amino-acid hydrophobic, proline/alanine-rich region within the proline-rich N-terminal domain; purified BTEB2 enhanced transcription in an in vitro transcription assay in a GC-box-dependent manner, and this activity was abolished by deletion of the hydrophobic region. Basic transcription factors TFIIB, TFIIEβ, TFIIFβ, and TBP were found to interact with BTEB2 by in vitro binding experiments.\",\n      \"method\": \"In vitro transcription assay with purified protein, deletion/point-mutation analysis, in vitro binding (pulldown) with basal transcription factors\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of transcription activity plus mutagenesis plus direct binding assays in one study\",\n      \"pmids\": [\"9089417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"KLF5 (BTEB2) binds the SE1 cis-regulatory element in the SMemb/NMHC-B gene promoter and activates its transcription in smooth muscle cells; a GST-BTEB2 fusion protein bound SE1 in a sequence-specific manner, BTEB2 was identified as a major component of the nuclear factor:SE1 complex by gel-shift and antibody supershift, and disruption of SE1 abolished basal and BTEB2-induced promoter activity.\",\n      \"method\": \"Gel mobility shift assay, antibody supershift, GST pulldown/DNA-binding assay, luciferase reporter with site-directed mutagenesis, immunohistochemistry\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal in vitro assays (EMSA, supershift, GST-DNA binding, mutagenesis of cis-element) in one study\",\n      \"pmids\": [\"10417400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"KLF5 (BTEB2) expression in vascular smooth muscle cells is transcriptionally activated by PMA and bFGF via an Egr-1 binding site (5'-CGCCCGCGC-3') located at -25 in the BTEB2 promoter, acting through the MAP kinase pathway; site-specific mutation of the Egr-1 site abolished inducible promoter activity.\",\n      \"method\": \"Luciferase reporter assay, site-directed mutagenesis, EMSA (DNA-protein complex characterization), pharmacological inhibition of MAPK pathway\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — promoter dissection with mutagenesis plus EMSA plus pathway inhibition in one study\",\n      \"pmids\": [\"10532946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Full-length human KLF5 (IKLF) encodes a 457-amino-acid nuclear protein that binds the CAAT/GT box (EGFRE) of the mouse lactoferrin gene promoter and represses reporter gene activity in RL95-2 endometrial carcinoma cells; nuclear localization was confirmed by GFP-tagged IKLF transfection and Western fractionation.\",\n      \"method\": \"DNase I footprinting, EMSA, GFP-tagging/fluorescence microscopy, Western blot of nuclear fractions, luciferase reporter assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct DNA-binding assays (footprinting, EMSA) plus localization and functional reporter in one study\",\n      \"pmids\": [\"10572182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"KLF5 (mBTEB2) is a transcriptional target of Wnt-1 signaling; its induction in C57MG cells occurs through a β-catenin/Lef-TCF-independent, PKC-sensitive noncanonical Wnt pathway, as shown by cDNA subtractive hybridization and pharmacological PKC manipulation.\",\n      \"method\": \"cDNA subtractive hybridization, transgenic mouse mammary gland analysis, PKC pharmacological inhibition, reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic/pharmacological pathway dissection in two model systems (cell line and transgenic mouse tissue), single lab\",\n      \"pmids\": [\"11134343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"KLF5 is induced by angiotensin II and in turn activates PDGF-A and TGF-β expression; KLF5 physically interacts with the retinoic acid receptor (RAR), and synthetic RAR ligands modulate KLF5 transcriptional activity; heterozygous Klf5-knockout mice showed diminished cardiovascular remodeling responses, and homozygous knockout caused early embryonic lethality.\",\n      \"method\": \"Heterozygous knockout mouse model, chromatin immunoprecipitation (ChIP) for PDGF-A promoter binding, co-immunoprecipitation (KLF5–RAR interaction), luciferase reporter assay, in vivo pharmacology with RAR ligands\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in vivo plus ChIP plus protein–protein interaction plus pharmacological modulation, independently replicated aspects across multiple follow-up papers\",\n      \"pmids\": [\"12101409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"KLF5 transactivation is enhanced by CBP; the interaction maps to the N-terminal region of CBP (aa 1–232) and the N-terminal region of KLF5 (aa 1–238). Phosphorylation at a PKC site within the CBP-interaction domain of KLF5 is required for full transactivation, as shown by kinase inhibitors and site-directed mutagenesis, and phosphorylation of KLF5 enhances its interaction with CBP in GST pulldown assays. The HAT activity of CBP does not acetylate KLF5 in vitro.\",\n      \"method\": \"GAL4 fusion transactivation assay, co-immunoprecipitation, GST pulldown, site-directed mutagenesis (PKC phosphorylation site), pharmacological kinase inhibition (H7, calphostin C)\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (reporter, Co-IP, GST pulldown, mutagenesis, kinase inhibition) in one study\",\n      \"pmids\": [\"12682370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"KLF5 binds the TCR Dbeta1 promoter GC-rich motifs and transactivates Dbeta1 germline transcription in pro-T cells; antibody supershift and chromatin immunoprecipitation confirmed endogenous KLF5 occupancy at the Dbeta1 promoter; a dominant-negative KLF5 construct inhibited reporter expression.\",\n      \"method\": \"Yeast one-hybrid screening, antibody supershift EMSA, chromatin immunoprecipitation (ChIP), luciferase reporter assay with dominant-negative construct\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP of endogenous locus plus dominant-negative functional validation plus EMSA supershift in one study\",\n      \"pmids\": [\"12576331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In non-transformed intestinal epithelial cells, KLF5 enhances cyclin D1 transcription and promotes cell growth; however, Ras-mediated transformation switches KLF5 function so that it reduces colony formation and no longer enhances cyclin D1 transcription, demonstrating context-dependent altered function during tumor progression. KLF5 protein is destabilized in transformed cells.\",\n      \"method\": \"Stable retroviral expression, colony formation assay, cyclin D1 luciferase reporter, Ras transformation model, protein stability analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in isogenic cell pairs plus reporter assays, single lab\",\n      \"pmids\": [\"14726538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TAZ stabilizes KLF5 protein by antagonizing WWP1-mediated ubiquitination; TAZ interacts with the PY motif of KLF5 through its WW domain, competing with the E3 ubiquitin ligase WWP1 for the same binding site, thereby inhibiting WWP1-mediated KLF5 ubiquitination and proteasomal degradation. This was shown to require the WW domain of TAZ and promotes breast cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, WW-domain mutant TAZ overexpression, siRNA knockdown, xenograft tumor model\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ubiquitination assay with domain-mutant controls, and in vivo rescue, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"22045023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"YAP interacts with KLF5 through its WW domains binding the PY motif of KLF5, preventing WWP1 E3 ligase from ubiquitinating KLF5, thereby stabilizing KLF5 protein and upregulating KLF5 target genes (FGFBP1/FGF-BP and ITGB2). LATS1 (upstream kinase of YAP) suppresses the KLF5-FGF-BP axis through YAP.\",\n      \"method\": \"Co-immunoprecipitation, WW-domain mutant YAP overexpression, siRNA knockdown, xenograft tumor model, target gene expression analysis\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain-mutant controls, epistasis via LATS1 knockdown, and in vivo xenograft, single lab multiple methods\",\n      \"pmids\": [\"22632819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FBW7 (FBXW7/CDC4) is an E3 ubiquitin ligase that targets KLF5 for ubiquitination and proteasomal degradation; KLF5 contains functional Cdc4 phospho-degrons (CPDs) required for FBW7 interaction; GSK3β phosphorylates these CPDs, and mutation of CPDs blocks FBW7-mediated ubiquitination and degradation of KLF5.\",\n      \"method\": \"Ubiquitination assay, co-immunoprecipitation, site-directed mutagenesis of phospho-degrons, GSK3β kinase involvement, cancer cell line and mouse model analysis\",\n      \"journal\": \"World journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanism reviewed and integrated from primary studies; CPD mutagenesis and Co-IP data cited from original papers by same group\",\n      \"pmids\": [\"24921010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BAP1 is a deubiquitinase (DUB) for KLF5; BAP1 directly interacts with KLF5 and stabilizes it via deubiquitination. KLF5 is present in the BAP1/HCF-1 complex. BAP1 knockdown inhibits tumorigenicity and lung metastasis, which is partially rescued by ectopic KLF5 expression. Identified by genome-wide siRNA DUB library screen.\",\n      \"method\": \"Genome-wide siRNA library screen, co-immunoprecipitation, deubiquitination assay, BAP1 knockdown with KLF5 rescue, xenograft/metastasis model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased genome-wide screen plus Co-IP plus biochemical DUB assay plus in vivo rescue experiment\",\n      \"pmids\": [\"26419610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cardiac myocyte KLF5 directly activates PPARα (Ppara) gene expression by binding its promoter; cardiac myocyte-specific Klf5 knockout mice showed reduced Ppara expression, reduced fatty acid oxidation, decreased ATP, increased triglyceride accumulation, and cardiac dysfunction. In septic hearts, c-Jun competes with KLF5 at an overlapping site on the Ppara promoter to repress transcription.\",\n      \"method\": \"Cardiac myocyte-specific knockout mouse, ChIP (KLF5 promoter binding), luciferase reporter assay, metabolic assays (FAO, ATP), co-IP or competitor binding analysis\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — tissue-specific KO with defined metabolic phenotype plus direct ChIP evidence of promoter binding, replicated concept across diabetes and sepsis models\",\n      \"pmids\": [\"26574507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In macrophages, KLF5 promotes podosome formation and cell migration by directly activating transcription of Myo9b (myosin IXB) through binding its promoter; KLF5 acts upstream of RhoA signaling (KLF5 knockdown increased RhoA-GTP levels); myeloid-specific Klf5 knockout mice showed impaired macrophage infiltration and reduced AAA formation.\",\n      \"method\": \"Myeloid-specific Klf5 knockout mice, luciferase reporter assay (Myo9b promoter), co-immunostaining, time-lapse migration imaging, RhoA-GTP pulldown assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO in vivo plus reporter assay with direct binding plus RhoA activity measurement, multiple orthogonal methods\",\n      \"pmids\": [\"28115390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HDAC1/2 deacetylate KLF5 at K369 and promote its proteasomal degradation; the deacetylase activity of HDAC1/2 is required for KLF5 degradation. An acetylation-mimicking K369Q mutation of KLF5 prevents its proteasomal degradation even though it does not affect HDAC1/2 binding. Maintaining KLF5 in a deacetylated state promotes cell proliferation.\",\n      \"method\": \"siRNA knockdown of HDAC1/2, site-directed mutagenesis (K369Q, K369R), cycloheximide chase/protein stability assay, co-immunoprecipitation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus stability assay plus Co-IP, single lab\",\n      \"pmids\": [\"29679567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"USP3 is a deubiquitinase for KLF5; USP3 interacts with KLF5 and stabilizes it via deubiquitination; USP3 knockdown inhibits breast cancer cell proliferation and tumorigenesis, which is partially rescued by ectopic KLF5 expression. Identified by genome-wide siRNA DUB library screening.\",\n      \"method\": \"Genome-wide siRNA DUB library screen, co-immunoprecipitation, deubiquitination assay, USP3 knockdown with KLF5 rescue, in vivo tumorigenesis model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — unbiased screen plus biochemical DUB assay plus in vivo rescue, single lab multiple methods\",\n      \"pmids\": [\"31624151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"KLF5 directly binds the promoter of NOX4 (NADPH oxidase 4) to activate its transcription; FOXO1 binds directly to the KLF5 promoter to increase KLF5 expression in diabetic cardiomyocytes; KLF5-induced NOX4 upregulation causes oxidative stress and ceramide accumulation leading to diabetic cardiomyopathy; cardiomyocyte-specific FOXO1 deletion reduced KLF5, and AAV-mediated KLF5 re-expression abolished this protection.\",\n      \"method\": \"ChIP (FOXO1 on KLF5 promoter; KLF5 on NOX4 promoter), cardiomyocyte-specific FOXO1 knockout mice, AAV-mediated KLF5 overexpression/rescue, pharmacological KLF5 inhibition, ROS/ceramide measurement\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP for direct promoter binding plus genetic KO plus AAV rescue in multiple mouse models with orthogonal biochemical readouts\",\n      \"pmids\": [\"33539225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Klf5 down-regulation in vascular smooth muscle cells leads to mitochondrial fission and vascular senescence; mechanistically, Klf5 directly activates eIF5a transcription by binding its promoter, and eIF5a in turn preserves mitochondrial integrity by interacting with mitofusin 1 (Mfn1). VSMC-specific Klf5 knockout mice showed exacerbated vascular senescence and AAA progression.\",\n      \"method\": \"VSMC-specific Klf5 knockout mice, ChIP (Klf5 binding to eIF5a promoter), co-immunoprecipitation (eIF5a–Mfn1 interaction), ROS measurement, mitochondrial imaging\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO plus ChIP plus Co-IP in same study, multiple orthogonal methods\",\n      \"pmids\": [\"32817651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Acetylated KLF5 (at K369) is the predominant form in basal prostate cells and is essential for proper luminal differentiation from basal progenitors; deacetylation of Klf5 (K369R knock-in) causes excess basal-to-luminal differentiation and activates Notch signaling; acetylated Klf5 maintains basal progenitors and coordinates postnatal prostate development.\",\n      \"method\": \"Acetylation-specific KLF5 K369R knock-in mouse, organoid assay, Notch signaling readout, cell lineage tracing, Western blot with acetylation-specific antibody\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — constitutive knock-in mouse model for a specific PTM plus organoid assays plus pathway readout, multiple orthogonal approaches\",\n      \"pmids\": [\"32081850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"KLF5 is a transcriptional regulator of skeletal muscle atrophy; KLF5 is up-regulated early in atrophying myotubes and skeletal muscle-selective Klf5 deletion attenuates mechanical unloading-induced atrophy in mice. KLF5 regulates atrophy-related metabolic and E3-ubiquitin ligase programs in coordination with Foxo1; the RAR agonist Am80 inhibits KLF5 and suppresses muscle atrophy.\",\n      \"method\": \"Skeletal muscle-specific Klf5 knockout mice, transcriptome profiling, chromatin accessibility analysis (ATAC-seq), pharmacological inhibition with Am80 (RAR agonist/KLF5 inhibitor), dexamethasone and simulated microgravity atrophy models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO mouse plus genome-wide chromatin and transcriptome analyses plus pharmacological rescue, multiple models\",\n      \"pmids\": [\"34426497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRMT5 interacts with KLF5 and catalyzes di-methylation of KLF5 at Arginine 57 (R57) in a methyltransferase-activity-dependent manner; PRMT5-induced KLF5 R57me2 antagonizes GSK3β-mediated KLF5 phosphorylation and subsequently Fbw7-mediated ubiquitination and degradation, thereby stabilizing KLF5 and promoting breast cancer stem cell maintenance and proliferation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro methylation assay, site-directed mutagenesis (R57), phosphorylation and ubiquitination assays, PRMT5 inhibitor (PJ-68), xenograft model\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro methylation assay plus mutagenesis of target site plus downstream PTM crosstalk analysis plus pharmacological and genetic validation in vivo\",\n      \"pmids\": [\"33972717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"KLF5 and AR physically interact on chromatin in prostate cancer cells and drive opposing transcriptional programs; KLF5 promotes cellular migration, anchorage-independent growth, and basal epithelial phenotypes while antagonizing AR activity. ERBB2 is identified as a point of transcriptional convergence activated by KLF5 and repressed by AR.\",\n      \"method\": \"Co-immunoprecipitation on chromatin, ChIP-seq, RNA-seq, gain- and loss-of-function (KLF5 overexpression/knockdown), ERBB2 inhibitor treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin Co-IP plus ChIP-seq plus transcriptomic plus functional assays, single lab multiple orthogonal methods\",\n      \"pmids\": [\"34737261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"YB-1 enhances KLF5 expression by: (1) transcriptional activation that can be inhibited by DACH1, and (2) stabilizing KLF5 mRNA in an RNA 5-methylcytosine modification-dependent manner. RSK2-mediated YB-1 phosphorylation at Ser102 promotes YB-1/KLF5 transcriptional complex formation, which co-regulates KRT16 and Ly6D expression to promote basal-like breast cancer cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation, mRNA stability assay, site-directed mutagenesis (YB-1 Ser102), ChIP, luciferase reporter, RSK inhibitor (LJH685) in vivo\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus mRNA stability plus mutagenesis, single lab\",\n      \"pmids\": [\"35022570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"KLF5 directly binds the promoter of COX2 and promotes its transcription; KLF5 deficiency decreases PGE2 release from tumor cells by reducing COX2 expression, thereby increasing CD8+ T-cell infiltration and function in the tumor microenvironment; inhibition of the KLF5/COX2 axis synergizes with anti-PD1 therapy.\",\n      \"method\": \"ChIP (KLF5 on COX2 promoter), luciferase reporter assay, RNA-seq, KLF5 knockout/overexpression in tumor cells, flow cytometry (T-cell infiltration), mouse tumor models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus in vivo functional assays, single lab\",\n      \"pmids\": [\"36923542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Klf5 establishes bi-potential cell fate in early mouse embryos by dual regulation: Klf5 directly induces both ICM specification genes and TE specification genes; Klf5 acts redundantly with Klf4 during ICM specification but Klf5 alone is required for TE specification. Klf5 is regulated by the 2C-specific factor Dux, and the Dux/Klf5 axis is evolutionarily conserved.\",\n      \"method\": \"ChIP-seq (direct target identification), Klf5 knockout embryos, chimeric embryo assay with Klf5-overexpressing ESCs, genetic epistasis (Klf5/Klf4 double mutant)\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq plus genetic KO plus chimeric embryo rescue plus epistasis analysis, multiple orthogonal approaches\",\n      \"pmids\": [\"34758315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"WWP2 monoubiquitinates KLF5 via its catalytic Cys838; monoubiquitination (not polyubiquitination/degradation) of KLF5 by WWP2 transactivates KLF5, promoting expression of downstream odontoblast differentiation genes Dmp1 and Dspp. WWP2 interaction requires the PY2 motif (PPPSY) of KLF5. Lysine residues K31, K52, K83, and K265 of KLF5 are essential for WWP2-mediated transactivation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K48-linkage analysis), site-directed mutagenesis (WWP2 C838A, KLF5 PY2 motif, KLF5 lysine residues), siRNA knockdown, ALP/Alizarin Red differentiation assays\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical ubiquitination assay with active-site mutagenesis plus substrate residue mapping plus functional differentiation readout, single lab multiple methods\",\n      \"pmids\": [\"33164644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HDACi (SAHA, TSA) increase KLF5 acetylation at K369 and promote its proteasomal degradation via ubiquitination; K369 acetylation decreases binding of KLF5 to its deubiquitinase BAP1, thus reducing KLF5 stability. This reveals a crosstalk between KLF5 acetylation (K369) and its ubiquitination/stability.\",\n      \"method\": \"Western blot with acetylation-specific antibody, ubiquitination assay, co-immunoprecipitation (KLF5–BAP1 interaction with K369 mutants), SAHA/TSA treatment, site-directed mutagenesis (K369)\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with acetylation mutants plus ubiquitination assay, single lab\",\n      \"pmids\": [\"35342356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Klf5 is an essential determinant of AT1 alveolar epithelial cell lineage fidelity during lung development; Klf5 represses AT2 cell proliferation and enhances AT2-to-AT1 cell differentiation in a spatially restricted manner during lung regeneration; Klf5 reduces AT2 cell sensitivity to inflammatory signaling to drive AT2-AT1 differentiation, as shown in infectious and non-infectious ARDS models.\",\n      \"method\": \"Cell-type-specific Klf5 conditional knockout mice, organoid assay, transcriptomic and epigenetic profiling, lung injury models (ARDS)\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO in multiple disease models plus organoid assays plus transcriptomic/epigenetic profiling\",\n      \"pmids\": [\"35803279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"α-Catulin interacts with the C-terminal region of KLF5 and inhibits WWP1-mediated degradation of KLF5, thereby stabilizing KLF5 and promoting cancer stem-like properties in non-small cell lung cancer; ILK inhibition disrupts the α-Catulin–KLF5 interaction and promotes KLF5 degradation.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, cycloheximide chase assay, ILK inhibitor treatment, sphere formation and xenograft assays\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus protein stability assay, single lab\",\n      \"pmids\": [\"35154481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SRC kinase-mediated tyrosine phosphorylation of YAP1 induces YAP1 interaction with KLF5 to form a YAP1/TEAD-KLF5 transcriptional complex; this complex promotes TEAD-mediated transcription independently of canonical Hippo kinases, driving cancer stemness and metastasis in TNBC.\",\n      \"method\": \"Co-immunoprecipitation, SRC inhibition, phospho-YAP1 mutant analysis, transcriptomic and proteomic analysis, TNBC xenograft and metastasis models\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus phospho-mutant analysis plus in vivo functional assays, single lab\",\n      \"pmids\": [\"36633714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KLF5 forms a transcriptional complex with EHF and ELF3 and binds to the promoter region of RAD51 to enhance its transcription, strengthening the homologous recombination repair (HRR) pathway; super-enhancers drive relative cancer-specific expression of KLF5 in ovarian cancer.\",\n      \"method\": \"ChIP (KLF5 on RAD51 promoter), co-immunoprecipitation (KLF5–EHF–ELF3 complex), super-enhancer analysis, luciferase reporter, functional HRR assay\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP plus reporter, single lab\",\n      \"pmids\": [\"37702443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRMT5 interacts with KLF5 and catalyzes dimethylation of KLF5 at Arginine 41 in lung cancer cells in a methyltransferase-activity-dependent manner; this methylation stabilizes KLF5 by promoting the Akt/GSK3β signaling axis, and PRMT5 depletion/inhibition reduces KLF5 expression and downstream targets.\",\n      \"method\": \"Co-immunoprecipitation, in vitro methylation assay, PRMT5 inhibitor treatment, Akt/GSK3β pathway analysis, siRNA knockdown, in vivo tumor model\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus methylation assay plus pathway analysis, single lab; note discrepancy in methylated Arg residue (R57 in breast cancer [33972717] vs R41 here — different contexts/residues reported)\",\n      \"pmids\": [\"37461162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PTEN deficiency induces KLF5 acetylation; deacetylated KLF5 in prostate cancer cells promotes secretion of TNF-α, which stimulates cancer-associated fibroblasts (CAFs) to release FGF9; FGF9 activates FGFR1 signaling in cancer cells, enhancing tumor growth; CX3CR1 inhibition blocked FGFR1 activation and sensitized PTEN-deficient prostate cancer to AKT inhibitor capivasertib.\",\n      \"method\": \"Klf5 acetylation knock-in mouse, co-culture assays (cancer cell–CAF interaction), cytokine ELISA, FGFR1 signaling analysis, pharmacological inhibition (CX3CR1 inhibitor + AKT inhibitor)\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knock-in mouse plus co-culture mechanistic dissection plus pharmacological rescue, single lab\",\n      \"pmids\": [\"38781024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Histone H3 lysine 14 lactylation (H3K14la), driven by elevated lactate in diabetic kidney disease, facilitates KLF5 expression at the chromatin level; KLF5 then binds the cdh1 (E-cadherin) promoter and inhibits its transcription, accelerating epithelial-mesenchymal transition. ChIP-seq revealed H3K14la at the KLF5 locus and RNA-seq linked this to EMT gene programs.\",\n      \"method\": \"ChIP-seq (H3K14la at KLF5 locus), RNA-seq, ChIP (KLF5 binding to cdh1 promoter), lactate reduction experiments, nephron-specific KLF5 knockdown mouse, KLF5 inhibitor (ML264)\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus ChIP plus nephron-specific KO, single lab\",\n      \"pmids\": [\"38925041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"KLF5 deacetylation (by HDAC1/2) is linked to its proteasomal degradation: silencing HDAC1/2 upregulates KLF5 protein without affecting mRNA, through reduced proteasomal degradation. An acetylation-mimicking K369Q mutation prevents KLF5 degradation, while a K369R mutation (blocks acetylation) does not affect HDAC1/2 binding or KLF5 degradation response.\",\n      \"method\": \"siRNA knockdown, cycloheximide chase, proteasome inhibitor MG132, site-directed mutagenesis (K369Q, K369R), co-immunoprecipitation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus protein stability assay plus Co-IP, single lab\",\n      \"pmids\": [\"29679567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"KLF5 promotes cell migration and lamellipodia formation in bladder cancer by transcriptionally activating FYN through direct binding to the FYN promoter; KLF5 overexpression increases FYN expression and FAK phosphorylation; FYN overexpression rescues migration reduced by KLF5 knockdown, placing KLF5 upstream of FYN in a KLF5/FYN/p-FAK migration axis.\",\n      \"method\": \"ChIP (KLF5 on FYN promoter), luciferase reporter assay, siRNA knockdown, FYN rescue experiment, lamellipodia imaging\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus epistasis rescue, single lab\",\n      \"pmids\": [\"26786295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In cancer chromatin, KLF5 interacts with TP63 and YAP1 transcription factors and with the CBP/EP300 acetyltransferase complex; KLF5 guides the CBP/EP300 complex to increase H3K27 acetylation, which enhances BRD4 recruitment; 3D chromatin looping (HiChIP) aggregates multiple distal KLF5 binding events to synergistically activate individual target genes and drive RNA Pol II elongation.\",\n      \"method\": \"HiChIP (3D chromatin architecture), immunoprecipitation-mass spectrometry (KLF5 interactome), ChIP-seq (H3K27ac, BRD4), PROTAC-mediated BRD4 degradation, KLF5 dependency screen\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — IP-MS interactome plus HiChIP 3D architecture plus ChIP-seq plus functional PROTAC validation, multiple orthogonal methods\",\n      \"pmids\": [\"33115806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"KLF5 is indispensable for maintaining basal progenitors in the intestinal stem cell niche; inducible deletion of Klf5 in Lgr5+ stem cells suppressed their proliferation and survival, associated with nuclear β-catenin localization and abnormal apoptosis; oncogenic β-catenin-driven adenoma/carcinoma production in Lgr5+ cells was completely suppressed by Klf5 deletion in the same cells, placing KLF5 downstream of or required for Wnt/β-catenin oncogenesis.\",\n      \"method\": \"Inducible Lgr5-specific Klf5 knockout mice, β-catenin nuclear localization analysis, oncogenic β-catenin knock-in crossed with Klf5 deletion, histological analysis of adenoma/carcinoma formation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible cell-type-specific KO plus oncogenic epistasis rescue, in vivo genetic model\",\n      \"pmids\": [\"24626089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Klf5 suppresses ERK signaling in mouse embryonic stem cells; Klf5-knockout ESCs showed over-activated ERK, reintroduction of Klf5 (but not Klf2 or Klf4) suppressed ERK. Klf5 regulates Spred1, a negative regulator of the FGF-ERK pathway, providing a molecular mechanism for ERK suppression.\",\n      \"method\": \"Klf5-KO ESC lines, ERK phosphorylation analysis, Klf5 re-expression (specificity comparison with Klf2, Klf4), Spred1 expression analysis, EpiSC reprogramming assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with rescue and paralog specificity test plus downstream target analysis, single lab\",\n      \"pmids\": [\"30452437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Simultaneous knockdown of KLF5 and Fli1 in dermal fibroblasts synergistically enhances connective tissue growth factor expression; double heterozygous Klf5/Fli1 mice spontaneously develop all three cardinal features of systemic sclerosis (fibrosis, vasculopathy, autoantibody production), establishing epigenetic co-downregulation of these two transcription factors as a central pathogenic event.\",\n      \"method\": \"siRNA double knockdown in primary fibroblasts, Klf5+/- Fli1+/- double heterozygous mouse model, histological/immunological phenotyping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-heterozygous mouse spontaneous disease model plus cellular knockdown epistasis, key mechanistic finding\",\n      \"pmids\": [\"25504335\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KLF5 is a nuclear zinc-finger transcription factor that binds GC-rich promoter elements to activate or repress target genes (including PDGF-A, TGF-β, PPARα, NOX4, COX2, SMemb/NMHC-B, FYN, RAD51, eIF5a, and others) and whose activity is tightly controlled by a network of post-translational modifications—phosphorylation (by PKC/GSK3β, promoting Fbw7-mediated ubiquitination and degradation), ubiquitination (by E3 ligases WWP1 and Fbw7, reversed by DUBs BAP1, USP3), acetylation at K369 (by p300/CBP, reversed by HDAC1/2, switching its proliferative to anti-proliferative function and affecting its stability and partner binding), and arginine methylation at R57/R41 by PRMT5 (antagonizing GSK3β-phosphorylation to stabilize KLF5)—while protein stability is also regulated by interacting partners YAP, TAZ, and α-Catulin that compete with WWP1 for the KLF5 PY motif; upstream, KLF5 expression is induced by angiotensin II, FOXO1, Egr-1/MAPK, and Wnt-1 (via noncanonical PKC-dependent pathway), and it interacts physically with RAR, CBP/EP300, AR, YAP1/TEAD, and other co-regulators to control cardiovascular remodeling, intestinal stem cell integrity, alveolar epithelial fate, prostate progenitor differentiation, skeletal muscle atrophy, and cancer cell proliferation/stemness.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"KLF5 (originally BTEB2/IKLF) is a GC-box-binding zinc-finger transcription factor that programs cell proliferation, differentiation, and lineage fidelity across cardiovascular, epithelial, embryonic, and cancer contexts, acting through three C-terminal zinc fingers that bind Sp1-like GC-rich elements and a proline-rich N-terminal activation domain that contacts the basal transcription machinery (TFIIB, TFIIE\\u03b2, TFIIF\\u03b2, TBP) [#0, #1]. At target promoters KLF5 directly activates or represses genes spanning vascular and metabolic remodeling\\u2014PDGF-A, TGF-\\u03b2, SMemb/NMHC-B, the lipid-oxidation regulator PPAR\\u03b1, the oxidant source NOX4, and the mitochondrial-protective factor eIF5a\\u2014and its loss drives cardiac dysfunction, vascular senescence, and aneurysm phenotypes in tissue-specific knockout mice [#2, #6, #14, #18, #19]. The same factor controls cell-fate decisions: it establishes bipotential ICM/trophectoderm fate in early embryos, maintains intestinal Lgr5+ stem cells and is required for \\u03b2-catenin-driven oncogenesis, enforces AT2-to-AT1 alveolar differentiation, and governs prostate basal/luminal balance [#26, #39, #29, #20]. In cancer, KLF5 promotes proliferation, migration, and stemness by activating targets including FYN, COX2, and RAD51 and by nucleating an enhancer machine in which it recruits the CBP/EP300 acetyltransferase complex together with TP63 and YAP1 to deposit H3K27ac, recruit BRD4, and drive Pol II elongation through 3D chromatin loops [#37, #25, #32, #38]. KLF5 abundance is set by a dense post-translational network: GSK3\\u03b2-primed phosphodegrons recruit the E3 ligase FBW7 for degradation, WWP1 ubiquitinates the PY motif, and these destabilizing events are opposed by deubiquitinases BAP1 and USP3, by PY-motif competitors YAP, TAZ, and \\u03b1-Catulin, and by PRMT5-catalyzed arginine methylation that antagonizes GSK3\\u03b2 phosphorylation [#12, #13, #17, #10, #11, #30, #22]. Acetylation at K369 by the CBP/EP300 axis, reversed by HDAC1/2, additionally toggles KLF5 between proliferative and differentiative outputs and modulates its stability by controlling BAP1 binding [#16, #20, #28]. WWP2-mediated monoubiquitination instead activates rather than degrades KLF5 to drive odontoblast differentiation genes, illustrating that distinct ubiquitin marks specify opposite functional fates [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the founding biochemical identity of KLF5 as a sequence-specific GC-box transcriptional activator, defining its DNA-binding and transactivation modules.\",\n      \"evidence\": \"cDNA cloning with recombinant DNA-binding (EMSA), reporter, and GAL4 fusion transactivation assays\",\n      \"pmids\": [\"8479902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological target genes not yet identified\", \"No cellular or in vivo context\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Localized the activation domain to a short hydrophobic proline/alanine-rich region and showed direct contact with the basal transcription machinery, explaining how KLF5 stimulates transcription.\",\n      \"evidence\": \"In vitro transcription with purified protein, deletion mutagenesis, pulldown with TFIIB/TFIIE\\u03b2/TFIIF\\u03b2/TBP\",\n      \"pmids\": [\"9089417\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interactions tested in vitro only\", \"No coactivator context beyond basal factors\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Connected KLF5 to vascular smooth muscle gene programs and defined its upstream induction by MAPK/Egr-1, placing it within stress-response signaling in the vasculature.\",\n      \"evidence\": \"EMSA/supershift, GST-DNA binding, reporter mutagenesis on SMemb/SE1 and the Egr-1 site of the KLF5 promoter, MAPK inhibition\",\n      \"pmids\": [\"10417400\", \"10532946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement not yet tested\", \"Whether repression vs activation is context-dependent unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated KLF5 can act as a repressor on a CAAT/GT-box target and confirmed nuclear localization, broadening its regulatory repertoire beyond activation.\",\n      \"evidence\": \"DNase I footprinting, EMSA, GFP localization, reporter assay in endometrial carcinoma cells\",\n      \"pmids\": [\"10572182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of activation vs repression not defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Provided the first in vivo genetic evidence that KLF5 drives cardiovascular remodeling through PDGF-A/TGF-\\u03b2 induction and is modulated by RAR, with homozygous loss being embryonic lethal.\",\n      \"evidence\": \"Heterozygous Klf5 knockout mice, ChIP on PDGF-A, KLF5\\u2013RAR co-IP, RAR-ligand pharmacology\",\n      \"pmids\": [\"12101409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific contributions not dissected\", \"Mechanism of RAR-dependent modulation incomplete\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed CBP coactivation of KLF5 requires PKC-dependent phosphorylation, linking signal-induced phosphorylation to coactivator recruitment.\",\n      \"evidence\": \"GAL4 transactivation, co-IP, GST pulldown, PKC-site mutagenesis, kinase inhibition\",\n      \"pmids\": [\"12682370\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Responsible PKC isoform and in vivo phosphosite not defined\", \"CBP HAT does not acetylate KLF5 in vitro\\u2014acetylating enzyme left open\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Extended KLF5 promoter occupancy to an endogenous immune locus (TCR Dbeta1), confirming functional chromatin binding in a distinct lineage.\",\n      \"evidence\": \"Yeast one-hybrid, supershift EMSA, ChIP, dominant-negative reporter assay\",\n      \"pmids\": [\"12576331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological role in T-cell development not tested in vivo\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Revealed that oncogenic Ras switches KLF5 from a cyclin D1-inducing growth promoter to a growth suppressor and destabilizes the protein, introducing the theme of context-dependent KLF5 function.\",\n      \"evidence\": \"Isogenic Ras-transformed intestinal epithelial cells, colony formation, cyclin D1 reporter, protein stability analysis\",\n      \"pmids\": [\"14726538\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of the functional switch undefined\", \"Single cell-line system\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the core degradation machinery for KLF5: GSK3\\u03b2-phosphorylated CPD degrons recruit FBW7 for ubiquitination, establishing the central phospho-degradation axis.\",\n      \"evidence\": \"Ubiquitination assay, co-IP, CPD mutagenesis, GSK3\\u03b2 involvement (review integrating primary data)\",\n      \"pmids\": [\"24921010\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Synthesized from prior primary work\", \"Kinase priming hierarchy not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed KLF5 within intestinal stem cell maintenance and made it genetically required for \\u03b2-catenin-driven tumorigenesis, and separately implicated it (with Fli1) in systemic sclerosis pathogenesis.\",\n      \"evidence\": \"Inducible Lgr5-Klf5 KO with oncogenic \\u03b2-catenin epistasis; Klf5/Fli1 double-heterozygous mouse fibrosis model\",\n      \"pmids\": [\"24626089\", \"25504335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in each setting not enumerated\", \"Relationship between stem-cell and disease roles unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified Hippo effectors YAP and TAZ as KLF5 stabilizers that competitively block WWP1 at the PY motif, coupling Hippo signaling to KLF5 protein levels and target gene output.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, WW-domain mutants, siRNA, xenografts\",\n      \"pmids\": [\"22045023\", \"22632819\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of YAP vs TAZ across tissues not resolved\", \"Stoichiometry of competition with WWP1 undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed KLF5 directly drives cardiac PPAR\\u03b1 and identified BAP1 as a stabilizing deubiquitinase, linking KLF5 to fatty-acid oxidation metabolism and to enzymatic ubiquitin removal.\",\n      \"evidence\": \"Cardiomyocyte-specific KO with metabolic phenotyping and ChIP; genome-wide DUB screen, DUB assay, in vivo rescue\",\n      \"pmids\": [\"26574507\", \"26419610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"c-Jun competition mechanism at the PPAR\\u03b1 promoter incompletely mapped\", \"BAP1/HCF-1 complex stoichiometry undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established KLF5 as a transcriptional driver of macrophage podosome formation and migration through Myo9b/RhoA, broadening its role into immune-cell motility and aneurysm pathology.\",\n      \"evidence\": \"Myeloid-specific KO, Myo9b reporter, migration imaging, RhoA-GTP pulldown\",\n      \"pmids\": [\"28115390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect RhoA regulation not fully separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined acetylation/deacetylation at K369 as a stability and function switch: HDAC1/2-mediated deacetylation promotes degradation while acetyl-mimic blocks it, and showed KLF5 suppresses ERK via Spred1 in ESCs.\",\n      \"evidence\": \"HDAC1/2 siRNA, K369Q/K369R mutagenesis, CHX chase, MG132, co-IP; Klf5-KO ESCs with paralog-specific rescue and Spred1 analysis; FYN transactivation in bladder cancer\",\n      \"pmids\": [\"29679567\", \"30452437\", \"26786295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzyme depositing K369 acetylation not identified here\", \"Single-lab stability data\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Added USP3 as a second stabilizing deubiquitinase, reinforcing that KLF5 levels are set by opposing ligase/DUB activities.\",\n      \"evidence\": \"Genome-wide DUB screen, co-IP, DUB assay, knockdown-rescue, in vivo tumorigenesis\",\n      \"pmids\": [\"31624151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate-site specificity of USP3 vs BAP1 undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple in vivo studies cemented KLF5 as a tissue lineage and metabolic determinant\\u2014alveolar AT1 fidelity, prostate basal progenitor maintenance via K369 acetylation, skeletal-muscle atrophy, and FOXO1\\u2192KLF5\\u2192NOX4 oxidative injury\\u2014and revealed a KLF5\\u2192eIF5a\\u2192Mfn1 axis preserving mitochondrial integrity.\",\n      \"evidence\": \"Cell-type-specific KO and acetylation knock-in mice, organoids, ChIP, ATAC-seq, AAV rescue, metabolic/ROS readouts\",\n      \"pmids\": [\"35803279\", \"32081850\", \"34426497\", \"33539225\", \"32817651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream selectivity directing KLF5 to opposing differentiation outcomes unclear\", \"How a single factor coordinates such divergent tissue programs unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved how KLF5 amplifies transcription mechanistically: it recruits the CBP/EP300 complex with TP63 and YAP1 to deposit H3K27ac, recruit BRD4, and aggregate distal binding events into 3D loops driving Pol II elongation.\",\n      \"evidence\": \"IP-MS interactome, HiChIP, H3K27ac/BRD4 ChIP-seq, PROTAC BRD4 degradation, dependency screen\",\n      \"pmids\": [\"33115806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this enhancer-machine mode operates outside cancer chromatin untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined arginine methylation as a stabilizing PTM\\u2014PRMT5 dimethylates KLF5 (R57 in breast cancer, R41 in lung) to antagonize GSK3\\u03b2 phosphorylation and FBW7 degradation\\u2014and clarified acetylation\\u2013ubiquitination crosstalk via reduced BAP1 binding.\",\n      \"evidence\": \"In vitro methylation assays, R57/R41 mutagenesis, PRMT5 inhibitors, PTM crosstalk and BAP1-binding analysis, xenografts\",\n      \"pmids\": [\"33972717\", \"37461162\", \"35342356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Discrepant methylated residue (R57 vs R41) across tissues not reconciled\", \"Some crosstalk data from single labs\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Detailed KLF5's combinatorial roles with other factors: opposing AR on chromatin to set basal/luminal prostate programs, partnering YB-1 in basal-like breast cancer, repressing COX2/PGE2 to shape anti-tumor immunity, and dual ICM/TE fate induction in embryos.\",\n      \"evidence\": \"Chromatin co-IP, ChIP-seq, RNA-seq, mRNA-stability assays, ChIP-seq embryo targets, KO/chimera epistasis, immune profiling\",\n      \"pmids\": [\"34737261\", \"35022570\", \"36923542\", \"34758315\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of KLF5-AR antagonism on shared loci incomplete\", \"COX2 axis tested in limited tumor models\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed ubiquitin-mark identity determines outcome: WWP2 monoubiquitination of KLF5 transactivates rather than degrades it to drive odontoblast differentiation, and \\u03b1-Catulin competes with WWP1 to stabilize KLF5 in lung cancer stemness.\",\n      \"evidence\": \"Ubiquitination assays with WWP2 C838A and KLF5 lysine/PY2 mutants, differentiation assays; yeast two-hybrid, co-IP, CHX chase, ILK inhibition\",\n      \"pmids\": [\"33164644\", \"35154481\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How mono- vs poly-ubiquitin marks are selected at shared lysines unclear\", \"Single-lab data for each interaction\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Expanded KLF5's cancer transcriptional partnerships\\u2014SRC-phospho-YAP1/TEAD complexes driving Hippo-independent stemness, and an EHF/ELF3-KLF5 complex activating RAD51 to bolster homologous recombination repair.\",\n      \"evidence\": \"Co-IP, SRC inhibition, phospho-YAP1 mutants, ChIP, super-enhancer analysis, HRR functional assay\",\n      \"pmids\": [\"36633714\", \"37702443\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect assembly of these complexes not fully resolved\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked KLF5 to non-cell-autonomous tumor signaling and chromatin metabolism: deacetylated KLF5 downstream of PTEN loss drives a TNF-\\u03b1/CAF/FGF9/FGFR1 paracrine loop, while lactate-driven H3K14 lactylation promotes KLF5 expression to repress E-cadherin and drive EMT in diabetic kidney disease.\",\n      \"evidence\": \"Acetylation knock-in mouse with co-culture and pharmacology; ChIP-seq H3K14la, ChIP on cdh1, nephron-specific knockdown\",\n      \"pmids\": [\"38781024\", \"38925041\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability of the paracrine loop beyond PTEN-null prostate cancer untested\", \"Lactylation\\u2192KLF5 chromatin mechanism single-study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single GC-box factor is directed toward opposite outcomes\\u2014proliferation vs differentiation, activation vs repression\\u2014across tissues, and how the combinatorial PTM code (phosphorylation, ubiquitination type, acetylation, methylation) is integrated at the level of partner choice and target selection.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model linking PTM state to partner/target selection\", \"Structural basis of PY-motif competition among YAP/TAZ/\\u03b1-Catulin/WWP1 undefined\", \"Reconciliation of opposing tissue functions absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 14, 18, 23, 26]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 4, 8]},\n      {\"term_id\": \"GO:0140223\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [38]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6, 14, 18, 38]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [26, 29, 20]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [12, 13, 22, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 31, 40]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [39, 41, 18]}\n    ],\n    \"complexes\": [\n      \"YAP1/TEAD-KLF5 transcriptional complex\",\n      \"KLF5-EHF-ELF3 complex\",\n      \"BAP1/HCF-1 complex\",\n      \"KLF5-CBP/EP300 acetyltransferase complex\"\n    ],\n    \"partners\": [\n      \"YAP1\",\n      \"TAZ\",\n      \"WWP1\",\n      \"FBXW7\",\n      \"BAP1\",\n      \"PRMT5\",\n      \"EP300\",\n      \"AR\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}